NewzIntel.com

    • Checkout Page
    • Contact Us
    • Default Redirect Page
    • Frontpage
    • Home-2
    • Home-3
    • Lost Password
    • Member Login
    • Member LogOut
    • Member TOS Page
    • My Account
    • NewzIntel Alert Control-Panel
    • NewzIntel Latest Reports
    • Post Views Counter
    • Privacy Policy
    • Public Individual Page
    • Register
    • Subscription Plan
    • Thank You Page

Category: vaccination

  • MIL-OSI Europe: World leaders recommit to immunisation amid global funding shortfall

    Source: Council of the European Union

    At the Global Summit: Health and Prosperity through Immunisation in Brussels, world leaders pledged support for Gavi, the Vaccine Alliance, leading to a total of more than $9 billion secured against a targeted $11.9 billion budget for its next five-year strategic period from 2026 to 2030 (Gavi 6.0). Additional donor commitments are expected in the coming months. 

    MIL OSI Europe News –

    June 26, 2025
  • MIL-OSI Europe: World leaders recommit to immunisation amid global funding shortfall

    Source: Council of the European Union

    At the Global Summit: Health and Prosperity through Immunisation in Brussels, world leaders pledged support for Gavi, the Vaccine Alliance, leading to a total of more than $9 billion secured against a targeted $11.9 billion budget for its next five-year strategic period from 2026 to 2030 (Gavi 6.0). Additional donor commitments are expected in the coming months. 

    MIL OSI Europe News –

    June 26, 2025
  • MIL-OSI Europe: World leaders recommit to immunisation amid global funding shortfall

    Source: Council of the European Union

    At the Global Summit: Health and Prosperity through Immunisation in Brussels, world leaders pledged support for Gavi, the Vaccine Alliance, leading to a total of more than $9 billion secured against a targeted $11.9 billion budget for its next five-year strategic period from 2026 to 2030 (Gavi 6.0). Additional donor commitments are expected in the coming months. 

    MIL OSI Europe News –

    June 26, 2025
  • MIL-OSI USA: Rep. Kelly questions Secretary Kennedy’s decision to reverse COVID-19 vaccine recommendations for pregnant women, children

    Source: United States House of Representatives – Congresswoman Robin Kelly IL

    WASHINGTON – U.S. Rep. Robin Kelly (Il-02) forcefully questioned Health and Human Services Secretary Robert F. Kennedy Jr. today as he appeared before the Energy and Commerce Health Subcommittee. She challenged his guidance change, announced through a video on X, ending COVID-19 vaccine recommendations for pregnant women and children.

    “It is clear that Health Secretary Kennedy received no serious input from medical experts in his unilateral decision to reverse COVID-19 vaccine recommendations,” said Rep. Kelly. “What concerns me is his lack of care for the consequences of his decision. Pregnant women are especially vulnerable to COVID – we saw that firsthand just a couple years ago when maternal deaths spiked during the pandemic.  Vaccines are safe, effective, and the best medicine to prevent outbreaks.”

    “Secretary Kennedy’s actions are proof that he is not fit for the job,” continued Rep. Kelly. “To the American people, take what Secretary Kennedy said to heart: do not take medical advice from him.”

    MIL OSI USA News –

    June 26, 2025
  • MIL-OSI USA: Majority Witnesses from PSI Hearing Submit Hundreds of Studies, Thousands of Citations Documenting COVID-19 Vaccine Adverse Events

    US Senate News:

    Source: United States Senator for Wisconsin Ron Johnson

    Minority witness submits 19 pro-COVID-19 vaccine citations after official hearing record closed 

    WASHINGTON – On Thursday, June 5, 2025, the official record closed for the Permanent Subcommittee on Investigations’ hearing entitled, “The Corruption of Science and Federal Health Agencies: How Health Officials Downplayed and Hid Myocarditis and Other Adverse Events Associated with the COVID-19 Vaccines.” Prior to its closure, the Majority’s witnesses submitted hundreds of documents — including peer-reviewed studies — and thousands of citations about COVID-19 vaccine adverse events to accompany their testimonies. These records provide substantial support for the witnesses’ claims regarding the serious health risks associated with the COVID-19 vaccines. 

    At the Subcommittee’s May 21, 2025 hearing, Chairman Ron Johnson (R-WI) released a Majority staff interim report and over 2,400 pages of records detailing the failure of Biden health officials to properly warn the public of the risks of myocarditis and related heart inflammation conditions following mRNA COVID-19 vaccination. The hearing featured testimony from Dr. Peter McCullough, Dr. Jordan Vaughn, Dr. James Thorp, Dr. Joel Wallskog, and Mr. Aaron Siri, all of whom were invited by Chairman Johnson to speak about COVID-19 vaccine adverse events.

    “Any of you who have cited some study or some opinion back it up, and we’ll include it in the hearing record. We’ll have this hearing record [] stay open for 15 days. So, I’m really encouraging people, send me that science,” Chairman Johnson stated to all witnesses at the hearing.

    Later, Chairman Johnson told Hawaii Governor Josh Green, the Minority’s witness at the hearing, “I’m begging you, please provide the studies, the citations that prove that the injection actually reduced severity of symptoms, prevented deaths. Give us those studies, so we can throw those into the hearing record and compare them to other studies[.]” Governor Green responded, “It will not be difficult, Senator, there’s so many.”

    In addition to the 33 pages Governor Green enclosed in his written statement for the hearing, Governor Green submitted 19 links to studies and articles to support his claims about the safety and efficacy of the COVID-19 vaccines. The governor’s submission to the record was made one week after the hearing record officially closed.   

    Chairman Johnson allowed Governor Green’s late submission to be included in the official record so that the public can compare the evidence that the governor presented in support of the COVID-19 vaccines to the multitude of documentation indicating the clear health risks associated with the injections.

    Documents and citations that the Majority’s witnesses entered into the record can be viewed here. Governor Green’s submission to the record can be viewed here.

    A video showing Chairman Johnson asking witnesses for citations can be viewed here. 

    MIL OSI USA News –

    June 26, 2025
  • MIL-OSI United Nations: Secretary-General’s video message at the Gavi High-Level Pledging Event – Global Summit: Health and Prosperity Through Immunization

    Source: United Nations secretary general

    Download the video:
    https://s3.us-east-1.amazonaws.com/downloads2.unmultimedia.org/public/video/evergreen/MSG+SG+/SG+4+Jun+25/3404655_MSG+SG+GLOBAL+SUMMIT+HEALTH+IMMUNISATION+04+JUN+25.mp4

    Excellencies,

    Distinguished guests,

    I thank the European Union, the Gates Foundation and Gavi, the Vaccine Alliance, for convening this crucial summit.

    Over the past fifty years, vaccines have saved over 150 million lives. 

    Every dollar invested yields 54 dollar in benefits.

    Gavi and its partners are the backbone of this success.

    But the work is far from done.

    Protecting 500 million more children by 2030 requires an urgent investment of at least nine billion dollars.

    Strong immunization programmes are our frontline defence against infectious diseases – and a foundation of resilient societies and economies.

    At a time when vaccine hesitancy and misinformation are spreading like wildfire, this investment is more crucial than ever.  Especially as other support is being rolled back.

    Today, I urge leaders across all sectors to act with generosity and resolve.

    Let’s invest in immunization for the health and prosperity of all.

    Thank you.
     

    MIL OSI United Nations News –

    June 26, 2025
  • MIL-OSI United Kingdom: UK partners with Gavi to help save up to eight million lives by 2030

    Source: United Kingdom – Executive Government & Departments 3

    Press release

    UK partners with Gavi to help save up to eight million lives by 2030

    New UK support will see millions of children vaccinated against some of the world’s deadliest diseases, Foreign Secretary David Lammy announced today at Gavi’s global summit in Brussels.

    • The UK will support Gavi as a leading investor in the Vaccine Alliance, committing £1.25 billion to vaccinate millions of children between 2026-2030.
    • The commitment will help Gavi protect up to 500 million children from some of the world’s deadliest diseases like meningitis, cholera and measles.
    • Gavi’s global vaccination work prevents the spread of dangerous infectious diseases while boosting investment and jobs in UK science as part of the Government’s Plan for Change.

    New UK support will see millions of children vaccinated against some of the world’s deadliest diseases, Foreign Secretary David Lammy announced today at Gavi’s global summit in Brussels.

    The UK’s new £1.25 billion pledge to Gavi, the Vaccine Alliance, extends a close 25-year partnership which has helped to vaccinate over one billion children globally against diseases like meningitis, to prevent more than 18 million lives being lost, and to improve countries economic prospects. Since 2000, when the UK was a founding member, Gavi has generated $250 billion in economic benefits through reduced death and disability. Gavi now receives investment from 56 countries and over 60 organisations. 19 countries have graduated from Gavi support, including India and Indonesia who have now become donors to Gavi.

    Today’s pledge will help Gavi in their mission to protect up to 500 million children between 2026-2030 and save up to eight million more lives.

    It will also have a positive impact at home, creating British jobs and growth, through partnerships with health companies like GSK, which employs about 14,000 people in the UK, as the government delivers on its Plan for Change to boost economic growth.

    Gavi helps strengthen the UK’s health security by preventing the spread of dangerous infectious diseases before they reach our borders. This reduces pressures on our hospitals and health workers, enabling an NHS fit for the future.

    UK Foreign Secretary, David Lammy said:

    Gavi’s global impact is undeniable. Over 1 billion children vaccinated, over 18 million lives saved, over $250 billion injected into the global economy.

    I’m immensely proud of the role the UK has played in reaching these milestones. Our ongoing partnership with Gavi will give millions of children a better start, save lives and protect us all from the spread of deadly diseases.

    GSK is a leading supplier to Gavi, providing vaccines for diseases like malaria and human papillomavirus (HPV). Their partnership supports UK research, science and innovation.

    Earlier this week, Minister for Development Baroness Chapman visited GSK’s research campus in Stevenage, alongside the Gavi CEO, Dr Sania Nishtar and and GSK’s President of Global Health, Deborah Waterhouse. Together they discussed some of the world-leading research being conducted by British scientists, including on new malaria and TB vaccines.

    UK Minister for Development, Jenny Chapman said:

    Our modern approach to development means focussing on where we can have the biggest impact, and on areas the UK can lead. We must ensure every pound delivers for the UK taxpayer and the people we support.

    Our partnership with Gavi does just that. It will save the lives of millions of children around the world, to grow up safe from deadly diseases like cholera and measles. And it will make the world and the UK healthier and safer, helping prevent future pandemics.

    It is partnership based on the UK’s world-leading expertise, not just money. By rolling out vaccines developed by British scientists, Gavi puts our best brains and their innovations on the world stage, and supports UK jobs and growth.

    CEO of Gavi, the Vaccine Alliance, Dr Sania Nishtar said:

    The United Kingdom is one of Gavi’s longest and most committed partners. This pledge for our next strategic period reaffirms its status as a leader in global health and I am delighted that we will be able to count on its support in our next strategic period, working together and leveraging some of the best in British science and innovation as we save lives and fight outbreaks around the world.

    President Global Health at GSK, Deborah Waterhouse said:

    The UK’s world-class infectious disease research continues to inform our work at GSK and combined with our scientific expertise, is enabling GSK to advance malaria prevention and control, directly impacting global health agendas and access strategies.

    As a longstanding partner of Gavi, the Vaccine Alliance – an organisation that plays a vital role in delivering vaccines to children in lower-income countries – we welcome the UK Government’s new pledge to Gavi, to help save up to eight million lives by 2030 and get ahead of disease together.

    Media enquiries

    Email newsdesk@fcdo.gov.uk

    Telephone 020 7008 3100

    Email the FCDO Newsdesk (monitored 24 hours a day) in the first instance, and we will respond as soon as possible.

    Share this page

    The following links open in a new tab

    • Share on Facebook (opens in new tab)
    • Share on Twitter (opens in new tab)

    Updates to this page

    Published 25 June 2025

    MIL OSI United Kingdom –

    June 26, 2025
  • MIL-OSI Europe: Speech by President António Costa at the Gavi’s High-Level Pledging Summit 2025

    Source: Council of the European Union

    On 25 June 2025, the EU co-hosted the Gavi 6.0 High-Level Pledging Summit. In his remarks, European Council President António Costa reaffirmed the EU’s unwavering commitment to global health and immunisation, highlighting Team Europe’s financial pledge to support Gavi’s mission of saving lives and strengthening health systems worldwide.

    MIL OSI Europe News –

    June 26, 2025
  • MIL-OSI Africa: Eritrea: Training of Trainers to Control Hepatitis B Virus Infection


    Download logo

    The Ministry of Health has organized a training of trainers program to introduce a vaccination initiative aimed at controlling Hepatitis B, a virus that causes liver inflammation and is transmitted vertically from mother to child. Representatives from regional health branches, vaccination program heads, and partners are participating in the training.

    Mr. Tedros Yihdego, Head of the National Vaccination Program at the Ministry of Health, stated that the objective of the training is to enhance understanding of the vaccination program, which is set to begin on 1 August and will administer the vaccine within the first 24 hours of birth.

    Dr. Nonso Ejiofor, WHO Representative in Eritrea, and Dr. Nande Putta, Chief of Child Survival and Development at UNICEF, noted that in Eritrea due to the equal implementation of the vaccination program in both urban and rural areas, the rates of infection and death have significantly declined. They expressed full support for the program.

    Mr. Tedros also expressed confidence that the national program will be successfully implemented through the coordinated participation of all relevant institutions.

    Distributed by APO Group on behalf of Ministry of Information, Eritrea.

    MIL OSI Africa –

    June 26, 2025
  • MIL-OSI Canada: Canada renews support to protect the world’s children against infectious diseases

    Source: Government of Canada News (2)

    June 25, 2025 – Ottawa, Ontario – Global Affairs Canada

    Vaccines are one of the world’s most effective, evidence-based health interventions. This is true no matter where in the world a child lives. Each year, Gavi, the Vaccine Alliance, provides immunizations for more than half the children born into the world, saving millions of them from life-threatening diseases like human papillomavirus (HPV), malaria, measles and polio.

    Today, the Honourable Randeep Sarai, Secretary of State (International Development), concluded his participation in Gavi’s pledging conference held in Brussels, Belgium, on June 25, 2025.

    At the conference, Secretary Sarai reiterated Canada’s renewed commitment to global immunization efforts through its previously announced pledge of $675 million over the next five years (2026-2030), for Gavi, The Vaccine Alliance.

    Gavi’s work has significant implications for global economic growth and health security and is projected to create more than $100 billion in economic benefits for supported countries over the next 5 years. Canada’s support will help Gavi provide life-saving vaccines to at least 500 million more children, preventing over 8 million deaths, protecting the world against future pandemics and disease outbreaks, as well as strengthening health systems and global health security. It will also support exciting innovations, including the rollout of the groundbreaking new malaria vaccine, as well as practical, climate-smart solutions, such as installing more than 20,000 solar-powered fridges and freezers to ensure life-saving doses stay cold in remote areas.

    On the sidelines of the conference, Secretary Sarai met with key leaders in global health, including representatives from implementing countries and heads of major organizations. These included Dr. Tedros Adhanom Ghebreyesus, Director-General of the WHO, Catherine Russell, UNICEF’s Executive Director, Dr. Mekdes Daba, Ethiopia’s Minister of Health, Dr. Muhammad Ali Pate, Nigeria’s Minister of Health, and Bill Gates. They discussed the future of global health efforts and the importance of sustained collaboration and innovation, to protect the progress made so far. Secretary Sarai also reaffirmed Canada’s steadfast commitment to Gavi and to making vaccines more accessible as the cornerstone of global health security.

    MIL OSI Canada News –

    June 26, 2025
  • MIL-OSI United Nations: 25 June 2025 Departmental update Momentum builds to protect immunization post World Health Assembly

    Source: World Health Organisation

    Several high-level side events were convened, including on measles and rubella, meningitis, polio and outbreak response, to elevate the critical role of immunization in protecting public health and building resilient systems. The declaration of 17 November as World Cervical Cancer Elimination Day also reinforced the global call to scale up HPV vaccination efforts. 

    The World Health Assembly also marked the midpoint of the Immunization Agenda 2030 (IA2030). As highlighted in WHO’s latest progress report, the world is not on track to meet IA2030 targets. Too many children remain unreached, and the consequences are visible in rising outbreaks of measles, yellow fever, and other vaccine-preventable diseases. Member States stressed the urgency of reaching “zero-dose” children and strengthening primary health care as the platform for integrated immunization services. 

    These challenges underscore the importance of Gavi, the Vaccine Alliance’s upcoming high-level pledging summit on 25 June, co-hosted by the European Union and the Gates Foundation. The summit aims to raise at least US$ 9 billion to support the next phase of Gavi’s strategy (2026–2030), which seeks to protect 500 million more children and save at least 8 million lives. The Director-General will join global partners to advocate for robust and sustained support, particularly in the face of climate-related emergencies, conflict, and pandemic threats. 

    As WHO and partners reaffirm the value of immunization as a health and economic investment—with a return of US$ 54 for every dollar spent—this is a defining moment to align political will, resources, and innovation to close the immunization gap and deliver on our IA2030 vision. 

    Click here to subscribe to the Global Immunization Newsletter.

    “,”datePublished”:”2025-06-25T08:04:07.0000000+00:00″,”image”:”https://www.who.int/images/default-source/searo—images/countries/timor-leste/5s-timor-leste/child-happy-after-receiving-health-checkup.jpg?sfvrsn=916df625_1″,”publisher”:{“@type”:”Organization”,”name”:”World Health Organization: WHO”,”logo”:{“@type”:”ImageObject”,”url”:”https://www.who.int/Images/SchemaOrg/schemaOrgLogo.jpg”,”width”:250,”height”:60}},”dateModified”:”2025-06-25T08:04:07.0000000+00:00″,”mainEntityOfPage”:”https://www.who.int/news/item/25-06-2025-momentum-builds-to-protect-immunization-post-world-health-assembly”,”@context”:”http://schema.org”,”@type”:”NewsArticle”};
    ]]>

    MIL OSI United Nations News –

    June 25, 2025
  • MIL-OSI United Kingdom: expert reaction to study suggesting adjuvants in certain vaccines may be one reason for their association with a reduction in dementia risk

    Source: United Kingdom – Executive Government & Departments

    June 25, 2025

    A study published in NPJ Vaccines looks at adjuvants in vaccines and their association with a lower risk of dementia. 

    Dr Julia Dudley, Head of Research at Alzheimer’s Research UK, said:

    “Dementia is not an inevitable part of ageing. Identifying ways to reduce dementia risk is a priority for research, and vaccination offers an intriguing area of exploration. There have been an increasing number of studies suggesting a link between people who receive certain vaccinations, like the Shingrix vaccine, and a decreased risk of dementia. This study offers a potentially different perspective on what might be linked to this finding.

    “In this latest large US-based observational study, researchers are proposing that it might be the adjuvant that is providing a protective effect, rather than the disease the vaccine is seeking to protect against. This study looked at dementia diagnoses in people who had received vaccines with the AS01 adjuvant and those who had a flu vaccine, which doesn’t contain this component.

    “An adjuvant is a substance in the vaccine used to create a boosted immune response, designed to give more effective protection upon exposure to the virus.AS01 is in the shingles vaccine Shingrix, and Arexvy, the vaccine to protect against respiratory syncytial virus (RSV).

    “They found people who had Shingrix, Arexvy or both of these vaccines were less likely to get a dementia diagnosis within 18 months. They found no difference between the Shingrix or Arexvy in terms of reducing dementia risk.

    “One of the strengths of the study is that it adjusted for factors that could influence risk, such as underlying health conditions and some lifestyle and environmental factors. However, as the study is observational and examined past health data, the researchers cannot conclude how the Shingrix and Arexvy vaccines may protect against dementia. We also cannot rule out that the link between vaccine and dementia risk is due to other factors not captured in this study, such as social and lifestyle factors.

    “One of the limitations highlighted by the authors was around people not having a dementia diagnosis when they could be living with the condition, which could skew the findings. We do not know if the adjuvant is reducing the risk of dementia or delaying its onset. The follow-up period was only 18 months, so more research is needed to determine the potential long-term effects of the vaccines.

    “As we understand more about the biological mechanisms behind any protective effects seen with vaccines, we may be able to investigate new treatment approaches.”

    Prof Kevin McConway, Emeritus Professor of Applied Statistics, Open University, said:

    “This is an interesting, worthwhile and statistically competent piece of work, but a lot more research needs to be done to make good sense of its possible implications for health care. In fact it’s a good example of how scientific and medical knowledge has to be built up through a series of studies, not just a single piece of work.

    “Previous research has provided pretty convincing evidence that vaccination against shingles, in older people, can reduce dementia risk. A recent study (published 2024), by the same research team responsible for the new study, found that the reduction in dementia risk is greater in people who had the shingles vaccine now in most widespread use, including in the UK (it’s called Shingrix), than with the previous vaccine (Zostavax).

    “However, that study could not provide direct evidence on the reason for the risk difference between the two shingles vaccines. One possibility is that having shingles might increase dementia risk, and that the new vaccine provides better protection against shingles than the old one did, so reducing dementia risk. Another is that there’s some component in the new vaccine that reduces dementia risk. Or it could be some combination of these possibilities.

    “The new Shingrix vaccine differs from the old Zostavax vaccine in several ways, but one difference is Shingrix vaccine contain a substance called AS01, while Zostavax does not. Some previous research has indicated that it’s possible that AS01 somehow provides in itself a reduction in dementia risk. AS01 is not the ingredient of the vaccine that directly incites the immune system to develop immunity against shingles. Instead it is an adjuvant – a substance that is intended to help the immune system to respond to the vaccination. 

    “AS01 is also used as an adjuvant in another vaccination offered to older people; the vaccination against the respiratory virus infection RSV (respiratory syncytial virus), which is now recommended for people in the UK aged 75-79.  One of the vaccines in use against RSV also contains AS01. (There’s another available vaccine that does not contain it.) So the research team responsible for the new study used data from a large set of American electronic health records, to compare dementia risk over a period of 18 months after vaccination for older people who had had various different vaccinations containing AS01 (just the RSV vaccine, just the shingles vaccine, or both). These people were compared with older people who had had a flu vaccine, not containing AS01.

    “The researchers found that those who had had either of the two AS01-containing vaccines (against RSV or shingles) had a lower risk of being diagnosed with dementia in the 18 months after vaccination than those who had had the flu vaccine. This pattern of lower risk showed up in people who had had just one of the AS01 vaccines, or both, though there were some relatively small (and statistically uncertain) differences in the average size of the risk reduction, compared to the flu vaccine, for different groups.

    “What’s still not known from this study is exactly why these risk differences occur. The researchers mention that, in some way, they could occur because having either RSV or shingles might in itself increase dementia risk, so that having a vaccine that makes it less likely to have one or both of those diseases might reduce dementia risk. Or it could be because of some protective effect of the AS01 adjuvant, which is in these vaccines but not in the flu vaccine. (Or some combination of these possible effects.)

    “The researchers give some arguments why they feel AS01 itself is likely to play a protective role against dementia. I don’t have expertise in virology so can’t comment directly on those arguments. But it’s at least a possibility, from all the existing evidence, that AS01 could have a protective effect. This study also doesn’t provide direct evidence on how AS01 might work to reduce dementia risk, but the researchers give some suggestions based on other studies as to what could be happening. Again I can’t comment on those.

    “It’s because of this inevitable lack of knowledge about exactly how AS01 might be involved in reducing dementia risk that the researchers are asking for more studies, some of them using other research methods, to find out more. I agree with this recommendation, because in my view the results of this study provide a clear justification for looking further. But we’re not yet anywhere near the stage of using the results of the new study to change clinical practice. Also, the new study can’t make the timescale of risk reduction very clear, because the follow-up period to look for dementia diagnoses was relatively short at 18 months.

    “This was an observational study – the people weren’t assigned at random to receive a particular pattern of vaccinations, but just did what they would have done anyway in consultation with health professionals. In any observational study, there can be issues about what is causing what. The basic problem is that people who receive different vaccinations will also differ in terms of many other factors – age, sex, what diseases they have previously had or still have, and many more. Some of these factors may be potential confounders, as they are called – that is, there’s a possibility that they are the cause of differences in dementia risk, and not the actual vaccinations at all. 

    “The researchers did a very thorough job of allowing for potential confounders, by doing something called propensity score matching. This involves setting up a statistical model that predicts people’s chances of having a dementia outcome, regardless of what vaccines they had had, and then matching people who (for example) had had the RSV vaccine but not the shingles vaccine with people who had had the flu vaccine. In this research the statistical model for the matching involves a very wide range of potential confounders. Then direct comparisons are based on these matched pairs of people. That means one can get a lot closer to comparing like with like groups, who don’t differ (on average) in terms of potential confounding factors.

    “The process can’t entirely avoid the possibility that there are confounding factors that couldn’t be dealt with in this way, and that’s why the research paper says clearly that unmeasured confounding can’t be entirely ruled out. So there has to remain doubt about whether the risk differences are caused by the different vaccines. This is in addition to the inevitable doubts about which aspects of the vaccines (AS01 or something else as well) might be causes of the risk differences – if indeed it’s the vaccines that do turn out to cause the differences. These are yet more reasons why this research is nowhere near being the last word.”

     

    Prof Sir Andrew Pollard FMedSci, Ashall Professor of Paediatric Infection and Immunity and Director of the Oxford Vaccine Group, University of Oxford, said:

    “There are now a number of studies which have shown an association between shingles vaccination in older adults and a reduced rate of dementia in the vaccinated population. The fact that two different vaccine platforms (both live attenuated shingles vaccines and the adjuvanted shingles subcomponent vaccine) saw similar associations supported the idea that the mechanism was as a result of vaccine-prevention of reactivation of the usually dormant shingles virus in the brain. Another virus from the same family, herpes simplex virus (the cold sore virus) has also been associated with dementia raising the possibility that both of these viruses (shingles and herpes simplex) could cause infection, possibly silently and recurrently, in the brain that led eventually to dementia. Unfortunately, there is no licensed vaccine for herpes simplex at this time. However, this latest study published in npj vaccines shows that another vaccine, against the completely unrelated respiratory virus, RSV, is also associated with a reduced rate of dementia. The authors argue that this is because of a non-specific effect of these vaccines on the immune system which generates an environment in our bodies which is somehow protective against dementia, though further studies are needed to confirm this. Such a mechanism could account for the effects driven by both shingles and RSV vaccines. The various studies of the impact of vaccination on dementia are all observational studies which could have a risk of bias, as it can be challenging to adequately control for differences between those who seek vaccination and those who don’t, but the consistent finding across multiple studies makes the observation more convincing. It is premature to be too certain about the mechanism by which vaccines might reduce dementia risk, but these observations provide further incentive for those eligible to turn up for their scheduled vaccination visits to prevent the unpleasant and potentially serious and life-threatening infections for which they were designed, but with the added possible benefit of a longer dementia-free life-span. What’s not to like?”

    ‘Lower risk of dementia with AS01- adjuvanted vaccination against shingles and respiratory syncytial virus infections’ by Maxime Taquet et al. was published in npj vaccines at 10:00 UK time Wednesday June 25th 2025. 

    DOI: 10.1038/s41541-025-01172-3

    Declared interests

    Prof Kevin McConway: No conflicts.

    For all other experts, no reply to our request for DOIs was received.

    MIL OSI United Kingdom –

    June 25, 2025
  • MIL-OSI United Kingdom: Get up to date with vaccines before holiday travel

    Source: City of Wolverhampton

    The warning follows recent data from the UK Health Security Agency (UKHSA), which highlights a rise in measles cases — particularly among unvaccinated children under the age of 10 – in various parts of the country. Similar surges are being seen across Europe and globally and, with increased travel over the summer holiday period, the risk of further cases is high.

    Measles is spread when an infected person breathes, coughs or sneezes and usually starts with cold-like symptoms, followed by a rash a few days later. Some people may also get small spots in their mouth.

    Measles usually starts to get better in about a week, but it can lead to serious problems if it spreads to other parts of the body, such as the lungs or brain.

    The MMR vaccine can prevent measles, mumps and rubella. It is offered to all children in the UK, and two doses can give lifelong protection. Parents and young people are urged to check their records and catch up if they’ve missed any doses.

    Alongside measles, residents are also being reminded of the serious risks posed by meningitis. The MenACWY vaccine, offered free to pupils in Year 9 and available through GPs up until the age of 25, protects against four key strains. Again, parents and young people are urged to check their records and book an appointment if they have missed it.

    Councillor Obaida Ahmed, Cabinet Member for Health, Wellbeing and Community, said: “Vaccines are one of the most powerful tools we have to keep ourselves and our loved ones safe. With rising measles cases and the risk of meningitis still very real, now is the time to act.

    “Whether you’re heading abroad or staying closer to home, it’s essential to check your family’s vaccination status – particularly for children. It’s never too late to catch up and get protected.”

    Residents are encouraged to review their child’s Red Book or contact their GP to confirm vaccination status. For more information, visit NHS or speak to your GP.

    MIL OSI United Kingdom –

    June 25, 2025
  • MIL-OSI United Kingdom: expert reaction to study looking at global childhood vaccination coverage

    Source: United Kingdom – Executive Government & Departments

    June 24, 2025

    A study published in the Lancet looks at global trends in routine childhood vaccination coverage.

    Dr Simon Clarke, Associate Professor in Cellular Microbiology, and Head of Division of Biomedical Sciences & Biomedical Engineering, University of Reading, said:

    “These figures indicate a worrying level of children in the UK who are completely unvaccinated against childhood diseases.  While the comparative data do not show the specific causes of this rising trend over recent decades, the WHO and others are right to highlight it as a worrying trend.

    “This is a very large assessment of multiple and large data sources, combined with models which are used to provide consistency between the data and provide forecasts into the future.  Such methodology provides both a clear overview of the past trajectories of immunisation rates along with an effective range of possible scenarios for the future, which appears to be robust and based on sound data.  The authors are clear about the limitations of their study but these do not detract from the overall message.

    “The current move away from funding global health schemes through international aid in order to spend more on defence puts the whole world at greater risk of future epidemics and pandemics.  Our security against this in the UK is improved by supporting efforts to not let dangerous diseases take hold in populations elsewhere in the world.  Our experience of Covid reminds us that lethal human diseases can be very hard to contain on the other side of international borders.”

    Dr David Elliman, Honorary Senior Associate Professor, UCL, said:

    “Vaccination is one of the most cost-effective ways that the health service can improve the lives of children around the world. It is a great success story with more vaccines being introduced all the time.  Not only does vaccination save lives, but it often saves money. However, in the last ten to twenty years, many countries, worldwide, have seen a reduction in the proportion of children receiving all the available vaccines. This article by a large group of researchers has documented the decline.  It may be difficult to measure uptake of vaccination accurately, but the researchers have allowed for this.  It is clear that the decline in uptake is happening around the world.  This has resulted in outbreaks of disease, for examples measles and whooping cough in USA and Europe (including UK) as well as in resource poor countries.  These diseases can and do kill children.  While part of the fall in vaccination is related to COVID, the trend was clear before then.

    “Declining vaccination rates are often blamed on misinformation, but there are many reasons, of which this is only one. Access to vaccines is often overlooked or underestimated as a factor, even in the UK.  Around the world, the increasing number of countries torn apart by civil unrest and wars, combined with the drastic cuts in foreign aid from rich nations, such as USA and UK, makes it difficult to get vaccines to many populations.  With the political changes in USA where it appears that policy is being made on the basis of ill-informed opinion, rather than science, we have a perfect storm. The researchers’ recommendations to strengthen primary health-care systems, address vaccine misinformation and hesitancy, and adapt to local contexts can, and should, be applied to all countries, including the UK.  In addition we should ensure that vaccines are available to all.

    “It is in everyone’s interest that this situation is rectified.  Not only is it a moral imperative to improve the health of ALL children, wherever possible, but as was said during the COVID pandemic, no-one is safe, until everyone is safe. While vaccine-preventable infectious diseases, occur anywhere in the world, we are all at risk. Universal vaccination is a perfect example of ‘enlightened self interest’.”

    Prof Sir Andrew Pollard FRCPCH FMedSci FRS, Director of the Oxford Vaccine Group, and Ashall Professor of Infection and Immunity, Pandemic Sciences Institute, University of Oxford, said:

    “The study uses an established approach to track the global burden of disease and immunisation coverage and the authors have tried hard to get the most accurate data by using multiple sources and account for regional variation and inequalities. These types of study will always be limited by the lack of high quality national data from most countries in the world which means there has to be extrapolation and assumption.  Nevertheless these are important data providing a concerning picture of recent declines in vaccine coverage and an increase in the number of zero dose children which risks the future health and lives of millions of children.

    “Incredible progress has been made in the past 50 years since the global expanded programme of immunisation was launched 50 years ago and over 150 million lives, mostly children, have been saved by the programme. The story is the same here in the UK with the launch of our own national programme by JCVI 62 years ago: deaths from infectious diseases of childhood have plummeted here too. The rarity of childhood severe disease and death from infection risks that we become complacent. But the danger remains out there: all of the diseases for which vaccines can protect children remain at large, only kept at bay by the shield which is provided by immunuisation. Unvaccinated children are vulnerable to a wide range of awful life-threatening bacteria and viruses, just as was the case for our population in the first half of the 20th century. There is a worrying trend of falling vaccine coverage worldwide which has been manifest in the last year as the outbreaks in Europe and North America of measles and whooping cough, with measles deaths in Texas in 2025. Falling global vaccine coverage, an increase in the numbers of children receiving no vaccines, and delays in vaccination mean that more children will be hospitalised, permanently damaged and die from fully preventable diseases if the trend is not reversed. Alas, the cuts in global health funding mean that this situation is set to deteriorate. This is a big concern for the future of our health and global health security.”

    Dr Ed Parker, Assistant Professor and Co-Director of the Vaccine Centre, London School of Hygiene & Tropical Medicine (LSHTM), said:

    “This is a timely study that attempts to quantify global trends in childhood vaccine coverage since 1980.  The findings highlight the remarkable progress that has been made to deliver life-saving vaccines across the globe, while painting a clear picture of the challenges faced following disrupted vaccination during the COVID-19 pandemic and the stagnation in vaccination rates that preceded it.

    “Underpinning the work is an immense data curation effort, drawing together data from household surveys, national coverage reports, and various other sources from across the globe. The study team estimated coverage trends with careful consideration of the biases, gaps, and inconsistencies that are inherent in these data, providing strong foundations for the study’s conclusions.

    “A key uncertainty – acknowledged by the authors – is that it is too early to know what effect proposed funding cuts might have on vaccination programmes globally. The recent resurgence of measles, polio, and diphtheria – all preventable by vaccination – serves as a reminder of what is at stake if high and equitable vaccine coverage is not sustained.”

    Prof Helen Bedford, Professor of Children’s Health, UCL, said:

    “It is often said that, after clean water, vaccination is the most effective intervention for protecting the health of our children. While it can be challenging in many settings to measure vaccine uptake accurately, the researchers publishing the latest data from the World Health Organization have made allowance for this and it provides powerful evidence. It is estimated that vaccination has prevented an estimated 154 million deaths, mostly in the under-fives, across the globe in the last 50 years. However, we cannot rest on our laurels; this progress is stalling in many countries including the UK. In UK, although vaccination is the norm, with the overwhelming majority of parents vaccinating their babies, infants and children without hesitation, there has been a small but gradual decline in the number of parents doing so each year over the past 12 years with increasing inequity in uptake between social groups. This has resulted in recent outbreaks of disease with the largest number of confirmed cases of measles since the 1990s and the tragic deaths of eleven babies from whooping cough in 2024.

    “The reasons for declining vaccine uptake are numerous and complex but require commitment and resource to meet the challenges of increasing social inequity, readily available mis-information about vaccine safety and necessity and improving public confidence in vaccination programmes. Vaccination remains one of our most powerful tools for protecting child health, but its continued success depends on sustained investment, equity, and public trust.”

    ‘Global, regional, and national trends in routine childhood vaccination coverage from 1980 to 2023 with forecasts to 2030: a systematic analysis for the Global Burden of Disease Study 2023’ by GBD 2023 Vaccine Coverage Collaborators was published in the Lancet at 23:30 UK time on Tuesday 24 June 2025. 

    DOI: 10.1016/S0140-6736(25)01037-2

    Declared interests

    Dr Simon Clarke: “No conflicts of interest.”

    Dr David Elliman: “No conflicts of interest.”

    Prof Sir Andrew Pollard: “Professor Pollard is chair of JCVI which provides independent scientific advice on vaccines to DHSC.  The comment above is given in a personal capacity.”

    Dr Ed Parker: “No COIs to declare.”

    Prof Helen Bedford: “No conflicts.”

    MIL OSI United Kingdom –

    June 25, 2025
  • MIL-OSI USA: Murray Calls for Kennedy to Reinstate Fired ACIP Members or Delay Meeting Until New Members Appropriately Vetted

    US Senate News:

    Source: United States Senator for Washington State Patty Murray

    ICYMI: Senator Murray, Former ACIP Member from WA State Raise Alarm Over Purge of Entire CDC Vaccine Advisory Committee

    Washington, D.C. – Today, Senator Patty Murray, a senior member and former chair of the Health, Education, Labor, and Pensions Committee released the following statement regarding the upcoming meeting of the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP), which is scheduled to begin tomorrow. The meeting would be the first since Secretary Kennedy fired every single member of the 17-member board, and announced his own slate of eight members just two weeks ago, many of whom have aligned themselves with dangerous anti-vaccine ideologies or outright conspiracy theorists and the majority of whom are not vaccine experts.

    “We need qualified vaccine experts evaluating the RSV and influenza shots families are counting on to protect them this fall—not the unvetted slate of eight members handpicked by RFK Jr. that includes people with long records of promoting anti-science conspiracies. The only way the upcoming ACIP meeting should proceed tomorrow is with the original board of vetted, qualified individuals that Secretary Kennedy chose to abruptly fire without any semblance of a legitimate reason or appropriate process. Short of that, ACIP must postpone this meeting until the board once again has a full slate of qualified members who have been fully and appropriately vetted.

    “It is perilous to move ahead with this meeting with a bench of largely unqualified members with anti-vaccine backgrounds who seem all but certain to set back public health and confidence in ACIP’s important work to protect Americans from deadly illnesses.”

    Earlier this month, Senator Murray held a press call with Washington state-based Dr. Helen Chu, one of the 17 ACIP members abruptly fired by Secretary Kennedy, to raise the alarm about how this move threatened public health and vaccine confidence.

    MIL OSI USA News –

    June 25, 2025
  • MIL-OSI USA: First Case of Measles Identified in North Carolina

    Source: US State of North Carolina

    Headline: First Case of Measles Identified in North Carolina

    First Case of Measles Identified in North Carolina
    stonizzo
    Tue, 06/24/2025 – 15:24

    The North Carolina Department of Health and Human Services has confirmed a case of measles in a child who was visiting Forsyth and Guilford counties. The child became ill while traveling to NC from another country where measles outbreaks have recently been reported. To protect the individual and their family’s privacy, no additional information about this individual will be released. This is the first confirmed case of measles in the state in 2025. NCDHHS is recommending all unvaccinated individuals ages one year and older receive measles vaccination to protect themselves and those around them. 

    NCDHHS is working closely with the Forsyth County Department of Public Health and Guilford County Health Department to identify locations and times where people might have been exposed to measles. 

    If you visited a listed location during the dates and times below, review your immunization records or contact your health care provider to make sure you are up to date on the measles-mumps-rubella (MMR) vaccine.
     

    Laboratory testing is not recommended for people who were exposed unless they develop symptoms of measles, including fever and rash. Symptoms of measles can start seven to 21 days after being exposed. If symptoms develop, please call ahead before visiting the doctor or emergency room so steps can be taken to prevent exposure to others. 

    In some situations, people who have been exposed to measles may be eligible to receive post-exposure prophylaxis (PEP) to reduce their risk of becoming ill. The timeframe for PEP has passed for most people who were potentially exposed to this case, but those who are at higher risk — including infants too young to receive MMR vaccination, immunocompromised individuals or pregnant women — should contact their doctor or local health department to see if PEP is needed.

    “Getting vaccinated against measles continues to be the most important step we can take to protect ourselves and our loved ones,” said NC Health and Human Services Secretary Dev Sangvai. “It is important to check with your health care provider to ensure you are current with all your vaccines.”  

    North Carolina residents can contact their health care provider or visit their local health department for additional information on ways to obtain the vaccine and schedule an appointment. Children eligible for the Vaccines for Children program may receive the vaccine from a provider enrolled in that program. For more information about measles, please visit dph.ncdhhs.gov/measles.

    To address this case, NCDHHS State Epidemiologist Zack Moore, M.D., MPH and partners from Forsyth and Guilford counties will be available to news media on Tuesday, June 24, at 4:30 p.m.  

    WHAT: NCDHHS virtual media availability on North Carolina’s first measles case and potential exposures  

    WHO: Dr. Zack Moore, State Epidemiologist, NCDHHS

               Joshua Swift, Director of Public Health, Forsyth County Department of Public Health

               Maura Trimble, Public Health Nursing Supervisor, Forsyth County Department of Public Health

               Susan Banville, Communicable Disease Nurse, Forsyth County Department of Public Health        

               Anita Ramachandran, Interim Director of Public Health, Guilford County Department of Health and Human Services

               LaTanya Pender, Clinical Services Director, Division of Public Health, Guilford County Department of Health and Human Services

               Tammy Koonce, Communicable Disease Nurse Consultant, Division of Public Health, Guilford County Department of Health and Human Services

    WHEN: Tuesday, June 24

                  4:30-5 p.m.

    WHERE: Zoom. Credentialed media should RSVP for the link by emailing news@dhhs.nc.gov

    Measles is a highly contagious, vaccine-preventable disease that is spread by direct person-to-person contact and through the air. The virus can live for up to two hours in the air where the infected person was present. Symptoms of measles usually begin 7-14 days after exposure, but can appear up to 21 days after exposure and may include:

    • High fever (may spike to more than 104 degrees)
    • Cough
    • Runny nose
    • Red, watery eyes (conjunctivitis)
    • Tiny white spots on the inner cheeks, gums and roof of the mouth (Koplik Spots) two to three days after symptoms begin
    • A rash that is red, raised, blotchy; usually starts on face, spreads to trunk, arms and legs three to five days after symptoms begin

    With the risk for community spread, parents are encouraged to make sure their children are up to date on all their childhood immunizations, including the measles vaccine. 90% percent of unvaccinated individuals who are exposed to measles will become infected. About one in five people who get measles will be hospitalized. In addition to North Carolina’s case, 1,214 measles cases have been reported in 2025 in 36 other jurisdictions as of June 19, 2025.  

    Jun 24, 2025

    MIL OSI USA News –

    June 25, 2025
  • MIL-OSI United Nations: Experts of the Committee on the Elimination of Discrimination against Women Commend the Voices of Afghan Women and Girls Demanding Justice, Ask about Discriminatory Laws and Edicts and the Ban on Education

    Source: United Nations – Geneva

    The Committee on the Elimination of Discrimination against Women today concluded its consideration of the fourth periodic report of Afghanistan, with Committee Experts extending profound appreciation to the women and girls of Afghanistan demanding justice, while raising concerns about the discriminatory laws and edicts imposed since the military takeover by the Taliban in 2021, and the ban on education. 

    Bandana Rana, Committee Expert and Country Rapporteur, extended profound appreciation to the women and girls of Afghanistan, whose voices continued to resonate across the world, demanding justice.  Another Expert urged all States parties to amplify the voices of Afghan women. 

    A Committee Expert said the dismantling of the Ministry of Women’s Affairs and replacing it with the Ministry of Vice and Virtue was a violation of article 3.  The law on vice and virtue silenced women’s voices in public and muffled their voices in private.  A March 2024 announcement enforced public flogging, and there had been numerous women publicly flogged for crimes ranging from adultery to dress code violations.  The reinstation of the stoning edict constituted torture and violated the rights to women’s liberty. 

    Another Committee Expert said education was one of the most important conditions for securing women and girls’ rights to equality.  Hence, it was deeply concerning that all eight sub-articles under article 10 were being violated by the State party.  Following the de facto authorities order to close secondary schools in 2021, schools today remained closed.  A shocking 30 per cent of girls in the State party did not even receive primary education.  All Afghan women and girls were entitled to receive full education.  Another concern was that young boys and girls were sent to religious madrasas where the curriculum was aligned with the most extreme versions of Islam. 

    In response to these comments and questions, the delegation said the edicts imposed by the de facto authorities amounted to gender apartheid.  The discrimination that women in Afghanistan faced was unparalleled globally.  There were no laws ensuring human rights in the country.  Women had been left to view these values as unattainable.  The Taliban de facto authorities had stated that Sharia law was the applicable legal framework in Afghanistan.  The Taliban had abolished mechanisms promoting gender equality, and projects promoting gender equality had ceased operations. 

    The delegation said the issue of education had been at the forefront of all of Afghanistan’s struggles and the international community’s demands.  The international community had continually emphasised the need for schools to open, and now there was no hope this would occur. There were currently efforts to implement small-scale education programmes on the ground.  This was better than nothing but could not address a systematic ban and an increasing number of jihadi madrasas.  There needed to be a mechanism to push the education project into Afghanistan, going over the Taliban’s restrictions, using technology. 

    Introducing the report, Nasir Ahmad Andisha, Permanent Representative of Afghanistan to the United Nations Office at Geneva, said that during the last review before the Committee in 2020, the delegation had been led by a woman from the Ministry of Women’s Affairs, which had since been abolished from the Government and replaced by the Ministry of Virtue and Vice.  Since August 2021, there had been over four years of systematic, widespread assault on every aspect of life of women and girls, a complete and total erasure and dehumanisation of women and girls in Afghanistan.

    The laws, policies and institutions that were once enacted to promote and protect women’s rights had been replaced with an intentionally designed edifice of oppression, including discriminatory edicts, decrees, declarations, orders, culminating in a so-called law on the promotion of virtue and the prevention of vice, Mr. Andisha said. 

    In closing remarks, Nahla Haidar, Committee Chair, said every member of the Committee was concerned and stood in solidarity with Afghanistan. This had been one of the most important considerations of a country report.  Ms. Haidar thanked all those from Afghanistan who came to share their views. 

    In his closing remarks, Mr. Andisha appreciated the opportunity to engage with the Committee. The Committee had created a vital pathway to ensure the voices of Afghan women and girls were heard.  Since August 2021, the situation for Afghan women and girls had deteriorated into a system of gender apartheid, which went against every article of the Convention.  It was time to listen, support and stand in solidarity with the women and girls of Afghanistan. They must be at the centre of every solution. 

    The delegation of Afghanistan was comprised of representatives of the National Human Rights Commission of Afghanistan; the Afghanistan Parliament; the Afghanistan Senate; the Ambassador of Afghanistan in Canada; the Ambassador of Afghanistan in Australia; the Ambassador of Afghanistan in Austria; the Administrative Reform Commission; Afghan diplomats; human rights activists; and the Permanent Mission of Afghanistan to the United Nations Office at Geneva.

    The Committee on the Elimination of Discrimination against Women’s ninety-first session is being held from 16 June to 4 July.  All documents relating to the Committee’s work, including reports submitted by States parties, can be found on the session’s webpage.  Meeting summary releases can be found here.  The webcast of the Committee’s public meetings can be accessed via the UN Web TV webpage.

    The Committee will next meet at 10 a.m. on Wednesday, 25 June to begin its consideration of the combined initial to fifth periodic reports of San Marino (CEDAW/C/SMR/1-5).

    Report

    The Committee has before it the fourth periodic report of Afghanistan (CEDAW/C/AFG/4).

    Presentation of Report

    NASIR AHMAD ANDISHA, Permanent Representative of Afghanistan to the United Nations Office at Geneva, thanked the Committee for undertaking this exceptional process despite the extraordinary situation in Afghanistan, where dark clouds overshadowed the lives of women and girls.  Afghanistan had ratified the Convention in 2003, without reservation, marking a landmark step forward for women’s rights in the country. 

    During the last review before the Committee in 2020, the delegation had been led by a woman from the Ministry of Women’s Affairs, which had since been abolished from the Government and replaced by the Ministry of Virtue and Vice.  Since August 2021, there had been over four years of systematic, widespread assault on every aspect of life of women and girls, a complete and total erasure and dehumanisation of women and girls in Afghanistan.  The laws, policies and institutions that were once enacted to promote and protect women’s rights had been replaced with an intentionally designed edifice of oppression, including discriminatory edicts, decrees, declarations, orders, culminating in a so-called law on the promotion of virtue and the prevention of vice. 

    Despite challenges in the preparation of the report, it aimed to provide a comprehensive and accurate account of the situation on the ground since 15 August 2021, reflecting an inclusive and participatory approach.  The report strove to ensure the international community took effective action based on verified information by proposing concrete recommendations for the path forward.  These recommendations aimed to offer hope, a vision, and a path forward towards the transformation of Afghanistan’s society through practical pathways for change in the lives of women and girls at a time when the Taliban de facto authorities had called the situation of women and girls an ‘internal’ matter”.   

    The Committee would hear how girls who still could attend school felt they needed to make the desperate choice to end their lives or were forced into marriage.  The dialogue today aimed to fulfil Afghanistan’s commitment to the international system.  Regardless of the Taliban’s approach, Afghanistan was taking its commitments to the international system seriously. 

    SIMA SAMAR, Former President of the National Human Rights Commission, said the dialogue today was exceptional.  The staff of the Afghanistan embassy did not have to defend themselves regarding the implementation of the Convention in the country.  The Committee and the Ambassador were on the same page.  The situation in Afghanistan was exceptional. After the removal of the Taliban in 2001, use of the word gender apartheid had stopped, and everyone thought they would never have to deal with this regime again.  Unfortunately, there was no other definition for what was happening in Afghanistan today. 

    Afghanistan had a unique situation.  The de facto authority aimed to erase women from public life and put restrictions on women without accountability and justice; this was a key core of their policies. All protection mechanisms established over the past 20 years had been abolished by the Taliban.  Afghanistan was the only Islamic country which had ratified the Convention without reservation.  The normalisation of the present violations of the human rights situation in Afghanistan was a scary concept.  The way Afghanistan now treated women led to a continuation of conflict. 

    FAWZIA KOOFI, Former member of the Afghanistan Parliament, thanked the Committee for listening to the women and girls of Afghanistan.  The women before the Committee were in a unique and tragic position; they were here to represent a State but they did not have a State.  It was emotional and heart wrenching.  Since the Taliban returned to power, women had been systemically excluded from every sphere of political and public life.  All mechanisms enabling women to participate in governance had been dismantled.  The Ministry of Women’s Affairs had been abolished and replaced by the Ministry of Vice and Virtue, which used the police to supress women’s autonomy. Women had been entirely excluded from the civil justice system.  Female prosecutors had been dismissed and faced security threats, particularly from former Taliban prisoners released on 15 August. 

    No female leaders were engaged in any decision-making processes at any level in Afghanistan. Women and girls were deliberately excluded from diplomatic negotiations and from international forums and engagements. Just one month after the Doha meeting, where no women were included, the law on vice and virtue was instigated, which effectively rendered women as second class citizens.  Girls could not attend school after a certain age but could attend madrasa schools which promoted radicalisation.  The Taliban needed to be held accountable for violations of the Convention. 

    SHUKRIA BARAKZAI, Former member of the Afghanistan Parliament, said today, Afghanistan was facing the worst system of gender apartheid. The de facto authorities had erased the legal identity of women and removed their presence from work and public life.  These were clear violations of international law and the Convention.  Yet despite this situation, Afghan women were showing resilience; their bravery must not go unnoticed.  The Committee was urged to recognise gender apartheid as a grave violation of the Convention; hold the de facto authorities accountable for systematic discrimination; and to support Afghan women inside and outside of the country. 

    In Iran, Afghan women could not buy food or use their credit cards.  Embassies had been shut down and were not providing simple documents. Recently, a new order was announced by the Taliban that female doctors and nurses could not go to their work without a male member of their family accompanying them (mahram).  The Convention should not just be a Convention, but an obligation. 

    Questions by a Committee Expert

    BANDANA RANA, Committee Expert and Country Rapporteur, extended profound appreciation to the women and girls of Afghanistan, whose voices continued to resonate across the world demanding justice.  The dialogue transcended mere procedure; it unfolded against the stark reality of one of the gravest human rights catastrophes confronting women and girls.  It was hoped that today’s exchange would prove constructive, anchored in mutual respect, steadfast commitment to strengthening accountability for the rights of Afghan women and girls.

    Since the de facto authorities assumed control, Afghan women and girls had suffered an unprecedented and systematic obliteration of their rights.  The prohibition of girls’ education beyond primary school, limitation to access to justice and healthcare, the wholesale exclusion of women from public and civic participation, and the systematic dismantling of constitutional protections constituted flagrant violations of the Convention’s fundamental principles.

    The Committee bore a solemn obligation, a legal, international and moral imperative, to examine these developments with unflinching clarity and uncompromising resolve. The Committee remained steadfast in its openness to future engagement.  To the de facto authorities, to States wielding influence, and to the international community at large: silence was complicity, not neutrality. It was hoped that today’s dialogue would serve to deepen the accountability of all stakeholders, and galvanise a renewed and unified commitment to restore the inalienable human rights of Afghan women and girls. 

    Since the takeover in August 2021, the de facto authorities had issued a sweeping series of edicts and decrees that institutionalised gender-based discrimination, directly violating article 1 of the Convention.  This discrimination was systemic and far-reaching, affecting every aspect of public, political, social, economic and cultural life.  Women and girls were barred from secondary and tertiary education, excluded from most forms of employment, severely restricted in their freedom of movement, and denied participation in political and public life. The Committee expressed its profound concern regarding these deep and entrenched violations.  The abolition of Afghanistan’s 2004 Constitution, and the dismantling of key legislative protection, including the law on the elimination of violence against women, were grave violations of article 2.  The inconsistent and opaque application of religious and customary law reinforced patriarchal norms, especially in areas such as family law, inheritance, and protection from violence, further entrenching gender inequality.

    The Committee was deeply alarmed by the erosion of legal institutions and access to justice. The dissolution of the Afghanistan Independent Human Rights Commission, closure of family courts, termination of women’s protection centres, and the cessation of legal aid services, dismantled essential accountability mechanisms for survivors of gender-based violence. Since August 2021, many non-governmental organizations had been forced to cease operations, suspend activities, or function underground.  Women human rights defenders were subjected to arbitrary detention, harassment and threats. 

    Prior to the 2021 takeover, Afghanistan had adopted a national action plan on United Nations Security Council resolution 1325, establishing a foundational framework for women’s participation in peacebuilding, conflict prevention, and reconstruction.  This framework had now been dismantled.  Afghanistan currently ranked last on the global women, peace and security index, reflecting the acute deterioration in women’s inclusion, access to justice, and personal safety.  The Committee remained gravely concerned about the systematic and institutionalised discrimination endured by women and girls in Afghanistan, and urgently called upon the de facto authorities and the international community to intensify its efforts, and to uphold the rights of Afghan women and girls in compliance with the Convention.

    Responses by the Delegation 

    The delegation said that the Organization of Islamic Cooperation had categorically rejected the Taliban’s assertion that its actions were based on Sharia law.  The 2004 Constitution had been dismantled by the Taliban.  Since August 2021, the Taliban had issued over 100 decrees which had the effect of segregating women and girls.  Every new decree aimed to further oppress women.  The Taliban had contravened every article in the Convention.  In its recommendations to the international community, the Committee was urged to refrain from normalising the Taliban’s activities; ensure any engagement with the Taliban de facto authorities was contingent on respect for the human rights of all, and promoted an equitable gender government; recognise and codify gender apartheid as an international crime; and adopt a new legitimate Constitution through a consultative process, among other measures. 

    Questions by Committee Experts

    A Committee Expert said the dismantling of the Ministry of Women’s Affairs and replacing it with the Ministry of Vice and Virtue was a violation of article 3.  The law on vice and virtue silenced women’s voices in public and muffled their voices in private.  A March 2024 announcement enforced public flogging, and there had been numerous women publicly flogged for crimes ranging from adultery to dress code violations.  The reinstation of the stoning edict constituted torture and violated the rights to women’s liberty.  Impunity in the criminal justice system eroded international law.  There were numerous punishments of women being beaten with whips, for cases such as making eye contact with men who were not family members. 

    The application by the Prosecutor of the International Criminal Court for arrest warrants broke new grounds, marking the first time gender persecution had been charged as a standalone charge.  Rape and other forms of sexual violence and forced marriage were violations of the Rome Statute.  These crimes may rise to the level of what was increasingly being recognised as a form of gender apartheid, which must be codified in the draft Convention on crimes against humanity.  All States parties were asked to amplify the voices of Afghan women. 

    Another Expert said the Committee expressed its deep concerns regarding the abolished efforts in the State party to increase women’s participation in public life through temporary special measures.  Between 2001 and 2021, several special measures were introduced by the previous government with the goal of achieving greater equality for women.  Among other policies, the election law reserved at least 25 per cent of the seats in each Provincial, District, and Village Council for female candidates.  Such laws and policies managed to increase the representation of women in Community Development Councils to almost 50 per cent in 2019 and in civil service from almost zero per cent during the previous regime (1996–2001) to 28 per cent in 2020. Yet, since taking power in 2021, the de facto authorities had dismantled all measures and programmes aimed at eliminating gender-based prejudices and promoting equality.

    The Committee called for all countries to employ whatever tools at their disposal to aid Afghan women and girls, including by putting in place special measures to deliver funding to local and international aid organizations, increasing quotas for resettlement of Afghani female refugees, and cooperating with neighbouring countries to ensure the safety of Afghani women in their territories.

    Responses by the Delegation

    The edicts imposed by the de facto authorities amounted to gender apartheid, the delegation said.  The discrimination that women in Afghanistan faced was unparalleled globally.  There were no laws ensuring human rights in the country.  Women had been left to view these values as unattainable.  The Taliban de facto authorities had stated that Sharia law was the applicable legal framework in Afghanistan.  The Taliban had abolished mechanisms promoting gender equality, and projects promoting gender equality had ceased operations.  All gender offices had been eliminated.  Women were left with no legal recourse.  Women faced considerable challenges to legal representation. 

    Questions by Committee Experts

    A Committee Expert said Afghan women underwent the worst forms of violence.  The Committee was alarmed by information provided by United Nations Women, including that instances of gender-based violence against women and girls had increased substantially.  The decrees published by the de facto authorities had remained dead letters due to the culture of impunity surrounding these acts.  These harmful practices did not respect the implementation of article 5 of the Convention and were flagrant violations of international law. 

    Another Expert said Afghanistan continued to serve as a transit and destination country for forced labour and sexual exploitation.  Many women had been coerced into prostitution and forced marriage. There were now not merely inadequate trafficking efforts, but the creation of conditions which made trafficking inevitable.  The December 2024 ban on women attending medical institutions had eliminated their last pathway to higher education.  This systematic exclusion violated several articles of the Convention and created a desperate situation which drove women towards trafficking. 

    The criminalisation of trafficking victims was highly alarming.  Women and girls could be charged for “zina” (sex outside of marriage) after being forced into trafficking.  It was acknowledged that the de facto authorities issued a decree around trafficking, however, this decree was inadequate compared to previous legislative frameworks.  The previous government’s efforts to coordinate trafficking efforts had been dismantled and there were no forms of victim identification.  There could be no effective trafficking response without full restoration of women’s rights. 

    Responses by the Delegation 

     

    The delegation said Islam and Sharia recognised and supported the rights of women and girls. The Taliban de facto authorities had weaponised their interpretation of culture and religion and systematically restricted every part of women’s lives.  These interpretations undermined the agency of women and girls.  Space for women was being limited under the pretence of “culture”.  The term “gender apartheid” should be codified. 

    Women and girls made up the majority of trafficking victims inside and outside Afghanistan. The de facto authorities made no effort to stop these crimes; shelters had been shut down and systems to prosecute traffickers had been dismantled.  Girls faced a higher risk due to being denied their rights to education. Many women were especially vulnerable, including those who were internally displaced.  The recent statement by some countries in support of women in Afghanistan was welcomed.  The Committee was urged to recommend that the international community took strong actions to protect women at risk.  The right to live free from violence, exploitation and trafficking was not optional.   

    Digital abuse had not received proper attention, and this was something which needed to be addressed. 

    Questions by Committee Experts

    A Committee Expert said previously, Afghan women had been active participants in politics, and by 2020 women comprised around one fifth of civil servants.  However, even during this period of progress, women had faced numerous threats in political life.  Women’s voices in peace processes remained largely ceremonial.  Since August 2021, the erasure of Afghan women from public and political life was deeply concerning.  The Expert condemned the dismantling of the Constitutional guarantee for 27 per cent of female political participation.  Not a single women served in the de facto administration. This stance starkly contravened the Convention.  The complete exclusion of women from the judiciary was extremely concerning. 

    Another Expert said the Committee was deeply concerned at the ongoing violations of Afghan women regarding their right to identity, including their inability to have access to identity documents.  Women in Afghanistan could not register the birth of their children and had to rely on a man to do it for them.  They were denied the possibility of transmitting their nationality to their children.  This situation was complicated when it came to women in situations of heightened risk. The lack of civil documentation affected a high percentage of women, putting them at a major risk of ending up as a victim of human trafficking.  There was a pressing need for States, multilateral organizations and those with a presence on the ground to work on a coordinated basis to support documents relating to civil documentation with a gender perspective. It was essential to roll out awareness raising campaigns targeting community and religious leaders. 

    BANDANA RANA, Committee Expert and Country Rapporteur, said the Committee expressed concern regarding the exclusion of Afghan women from international discussions, including the Doha talks.  Refugee and asylum-seeking women must have access to gender sensitive asylum procedures. All host and transit States were urged to uphold their obligations under the Convention. 

    Responses by the Delegation 

    The delegation said female representation across Afghanistan had previously been comprised of 35 per cent of women and was now at zero per cent.  Now that public space was completely closed to women, this space was only provided by the United Nations.  Recently, there had been reports that United Nations female staff were detained by the Taliban. 

    It was currently much more difficult for women in Afghanistan to receive a passport.  If they were single, then they needed a man to go with them to apply.  This had stripped women from fully enjoying their rights as country nationals.  It was difficult to see the de facto authorities appointing females to represent Afghanistan on an international level. 

    Questions by Committee Experts

    A Committee Expert said education was one of the most important conditions for securing women and girls’ rights to equality.  Hence, it was deeply concerning that all eight sub-articles under article 10 were being violated by the State party.  In 2017, more than one third of the student population were girls.  The Constitution and national law provided the right to education without discrimination, and women regularly entered higher education. Following the de facto authorities order to close secondary schools in 2021, schools today remained closed.  A shocking 30 per cent of girls in the State party did not even receive primary education.  All Afghan women and girls were entitled to receive full education. 

    Another concern was that young boys and girls were sent to religious madrasas where the curriculum was aligned with the most extreme versions of Islam.  The exclusion of half the population from education aimed to erase women and girls from public and intellectual life.  These restrictions had led to a rise in early marriage and child labour, and deepened poverty in an already poor country.  The de-facto authorities must reverse all education bans and allow girls to receive an education; there must be pressure from the international community to ensure this occurred. 

    BANDANA RANA, Committee Expert and Country Rapporteur, said host countries were obliged under the Convention to ensure equal education opportunities for Afghan girls who were refugees. 

    Responses by the Delegation 

    The delegation said the issue of education had been at the forefront of all of Afghanistan’s struggles and the international community’s demands.  The international community had continually emphasised the need for schools to open, and now there was no hope this would occur. There were currently efforts to implement small-scale education programmes on the ground.  This was better than nothing, but could not address a systematic ban and an increasing number of jihadi madrasas.  In a few years, there would be female Taliban supporters leaving these institutions.  There needed to be a mechanism to push the education project into Afghanistan, going over the Taliban’s restrictions, using technology. 

    Questions by a Committee Expert

    A Committee Expert said the Committee expressed deep concern at the erosion of Afghan’s women’s right to work.  Most female civil servants had been barred from returning to their jobs since the de facto authorities assumed power in 2021.  In 2022, Afghan women were banned from working for non-governmental organizations, as well as United Nations organizations.  The requirement for a male guardian had resulted in women being stopped from commuting to work all together.  Women in formal labour dropped from around 14 per cent in 2021 to just five per cent in 2023.  Women headed households had been disproportionately impacted by poverty. This was a national development crisis requiring urgent international action.  The right to work was a core human right, fundamental to human dignity and social stability. 

    Responses by the Delegation 

     

    The delegation said the Taliban de facto authorities had banned women from working in non-governmental organizations.  The loss of this infrastructure had most severely affected the country’s most vulnerable.  Today the majority of Afghan women were excluded from income-generating activities. Unleashing women’s economic potential would unlock the future of the country.  Excluding women had cost the Afghan economy almost a billion dollars. Previously, women had been very active in the private sector and in the civil service.  It had been almost two years that women who had retired were not receiving their pensions, which made the situation even more difficult. 

    Questions by a Committee Expert

    A Committee Expert said the Committee was concerned about the health situation of women in Afghanistan and their access to basic health services.  The systematic restrictive measures taken by the de facto authorities had seriously impacted women’s access to health care.  They faced greater barriers to accessing health care owing to scarce resources and cultural norms, which only allowed women to be treated by women.  Afghanistan had one of the highest child mortality rates in the world, with around 625 deaths per 100,000 births.  This rate was higher in rural and remote areas.  Women had reported high rates of bad mental health and accounted for the majority of suicide attempts.  The Taliban’s disregard of the health of women was a violation of the Convention. The de facto authorities must lift relevant restrictions to create a social and cultural environment conducive to women’s physical and mental health.  It was also hoped that the international community would call on Afghanistan to rebuild its healthcare system and reintroduce the training of female health care professionals. 

    Responses by the Delegation

    The delegation said access to health, and the reduction in maternal and child mortality had been areas where Afghanistan had made phenomenal progress before 2021. Unfortunately, the past four years of reversal had almost washed away all these achievements. 

    Reports of desperation, anxiety and suicide were widespread and worsening.  No mental health support was available to women. The ability of women to access medical treatment had been severely constricted, as they were denied healthcare without a male guardian.  Many women in rural areas died during childbirth due to a lack of resources. The number of female doctors and midwives had already been insufficient before the ban.  The closing of midwife schools could mean that in 10 years, there would be no trained midwives.  The Committee was urged to consider increasing offers to support medical and consulting services and create a safe space, shelter and support centre for those in exile.     

    Access to education was the strongest tool for empowerment; the Taliban was denying this access to restrict the empowerment of women and control them.  The connection between health and education was undeniable, as education gave women and girls the opportunity to choose their profession and their lives.  The radicalisation of girls in the family was also a frightening concept for the country. 

    Questions by a Committee Expert

    An Expert said following the Taliban takeover, sanitation and water infrastructure in Afghanistan had collapsed, drastically impacting women and girls.  The restriction of hammams had also restricted women’s hygiene.   

    Responses by the Delegation

    The delegation said the policies of the Taliban directly attacked the mental health of women in Afghanistan.  Young girls also did not receive iron tablets from the schools under Taliban rule, and periods were considered taboo.  Vaccinations had now been banned and Afghanistan was the only country with cases of polio. 

    Questions by a Committee Expert

    An Expert said it was alarming that over 90 per cent of the population had been plunged into poverty.  Women were banished from economic activity and struggled to meet basic needs.  The economy had sharply declined.  It was perturbing that only 6.8 per cent of women had a personal or joint bank account, compared to 21 per cent of men. There was grave concern that the lockout of women and girls from businesses had stifled the economy.  The international community and private sector trading partners were urged to increase pressure to uphold women and girls as critical contributors to the economy. 

    Responses by the Delegation

    The delegation said since the Taliban’s military takeover, all economic activity by women had ceased after it had been driven underground or was conducted by male intermediaries.  Women-led households were confronting impossible choices, including forced marriage or the sale of children.  Families were trading household belongings or their daughters for survival.  There was no functioning social safety net; pensions had been stripped away.  Women were increasingly barred from inheriting or owning land, homes or other assets.  Over 40 public libraries and community art centres had been shut down since April. Female artists had fled to exile and those who remained lived in fear.  Women’s access to financial resources needed to be enhanced, as did women’s access to cultural opportunities.  These were essential to rebuilding Afghanistan. 

    Questions by a Committee Expert

    An Expert said rural women no longer had access to land or credit and had been nearly totally erased from public spaces.  The Committee was alarmed about the near collapse of maternal and reproductive healthcare in rural areas.  Women with disabilities faced systemic neglect and heightened exposure to abuse. The Committee was also concerned about the forced and mass return of Afghan nationals from Iran and Pakistan since 2023.  The plight of child widows and orphaned girls in rural regions was also alarming.  This violation represented a widespread denial of the rights recognised under the Convention.  Women and girls were also being excluded from technology, including artificial intelligence. 

    Responses by the Delegation

    The delegation said the discrimination faced by women in Afghanistan was even worse for rural women, and those from diverse ethnic groups.  Women human rights defenders were especially at risk.  Rural women were also hit harder by climate change and disasters, with no system to help them recover.  The Committee was urged to ensure that women and civil society inside Afghanistan were able to participate in the development of strategies conducive to the Convention.  Even a cell phone in Afghanistan was not considered personal property; all communications were checked.  All Afghan women were facing the same type of discrimination, whatever their ethnicity, religion or where they lived.  The Olympic Committee in Afghanistan was under the control of the Taliban; the Committee was called on to show support for Afghan athletes, who were largely based outside of Afghanistan. 

    Questions by a Committee Expert

    A Committee Expert said the access of women to inheritance was an area where there had been modest progress.  Courts were currently led by male religious leaders.  Forced marriage and child marriage were other concerning areas. Divorce for women had become almost impossible in practice.  Gender-based violence in Afghanistan had increased significantly in a context of impunity.  The authorities were recommended to establish basic guarantees for women and girls in line with international human rights standards.  The explicit prohibition needed to be outlined, and 18 needed to be laid out as the minimum age for marriage. 

    Responses by the Delegation

     

    The delegation said the arbitrary arrests of women human rights defenders and activists further undermined the Convention.  Nearly 80 per cent of young women were now excluded from education and employment opportunities.  As such, forced and child marriage increased significantly.  Forced marriage denied women autonomy and led to gender-based violence and risk of death.  The international community was urged to support grassroots organizations working for women’s equality, especially women-led organizations. 

    The decline of gender equality was a global trend.  It was hard for Afghan women and girls to find their way; sometimes they were banned by their own international allies.  How could the women make themselves relevant?  The Committee had a huge responsibility in this regard.  Due urgency had not been given while Afghanistan was losing generations of women.  There needed to be space for the people of Afghanistan to create their own narrative for their country.  Women should be put in the driving seat; they knew how to fix their country. 

    The Taliban had engaged in acts of polygamy with underage girls.  They had cancelled all court orders for women seeking divorce. There was no longer a body to make law in Afghanistan and there was no Constitution.  The Committee must be more than a monitoring body; it needed to be a defender of justice.  Afghan women needed more than a statement; they needed action. 

    Closing Remarks

    NAHLA HAIDAR, Committee Chair, said every member of the Committee was concerned and stood in solidarity with Afghanistan.  The Committee Experts did not represent Governments, but they could speak to all States parties.  Within their limited authority and mandate, they were doing all they possibly could to carry the voices of the women in Afghanistan to those who could take action. It was frustrating when the Committee’s concluding observations did not translate into action.  The action was not necessarily in the hands of the Committee, but they would pave the way for it.  This had been one of the most important considerations of a country report. Ms. Haidar thanked all those from Afghanistan who came to share their views. 

    BANDANA RANA, Committee Expert and Country Rapporteur, said the Committee would do everything within its mandate to improve the rights of women and girls in Afghanistan.  The Committee called on the de facto authorities to restore women’s rights as a matter of urgency, and for the international community’s support.  Ms. Rana thanked all those from Afghanistan who had shared their experiences with the Committee. 

    SIMA SAMAR, Former President of the National Human Rights Commission, thanked the Committee for protecting women’s rights around the world.  Having a lack of female representation was a threat to peace and security.  Ms. Samar thanked the Committee Experts for their solidarity with the women of Afghanistan. 

    NASIR AHMAD ANDISHA, Permanent Representative of Afghanistan to the United Nations Office at Geneva, said he appreciated the opportunity to engage with the Committee. The Committee had created a vital pathway to ensure the voices of Afghan women and girls were heard.  Since August 2021, the situation for Afghan women and girls had deteriorated into a system of gender apartheid, which went against every article of the Convention.  Afghanistan’s women and girls may be denied their dignity, but they were the strongest advocates of human rights. 

    The Committee was urged to expand its procedures in response to the situation in Afghanistan, including to cooperate with the Committee on the Rights of Persons with Disabilities, which allowed for individual complaints.  States were urged to establish a gender response and accountability mechanism.  The human rights system should improve coordination across the United Nations system, with a view to promoting and protecting human rights.  It was time to listen, support and stand in solidarity with the women and girls of Afghanistan.  They must be at the centre of every solution. 

    ___________

    Produced by the United Nations Information Service in Geneva for use of the media; 
    not an official record. English and French versions of our releases are different as they are the product of two separate coverage teams that work independently.

    CEDAW25.017E

    MIL OSI United Nations News –

    June 25, 2025
  • MIL-OSI New Zealand: GPs to receive record funding boost

    Source: New Zealand Government

    General practices are set to benefit from the largest funding boost in New Zealand’s history – because frontline care starts with your local GP, Health Minister Simeon Brown says. 

    “This Government is focused on real results. When you are able to see your doctor or nurse earlier, you stay healthier and out of hospital. That’s better for patients, better for the system, and exactly what we are here to deliver,” Mr Brown says.

    “Too many New Zealanders have struggled to get care because their local GP isn’t taking new patients, or the next available appointment is weeks away. This funding boost is about turning things around. It’s part of our $1.37 billion investment in Health New Zealand through Budget 2025 – backing your local family doctor to see more patients, reduce wait times, and deliver care faster to those who need it most.

    “The funding agreement reached with the sector yesterday reflects another significant step forward and will support GPs to continue to improve access to timely, quality healthcare.”

    Under the agreement, GPs will receive a 13.89 per cent funding uplift this year. This brings the total Government funding increase for GP clinics this financial year to $175 million – more than double the highest annual increase seen since capitation was first rolled out.

    “This reflects our ongoing commitment to strengthen and invest in frontline services to ensure New Zealanders can get access to the timely, quality healthcare they deserve.

    “We have already announced major investments to boost the number of doctors and nurses working in primary care. This funding boost will enable GP clinics to recruit and retain the additional workers as they graduate.”

    This funding increase provides: 
     

    • $59 million capitation increase for the number of patients enrolled with individual general practices
    • $60 million for improved patient access to appointments, and to encourage practices to provide more data to enable more performance-based funding
    • $30 million performance-based funding for improved immunisation outcomes, specifically ensuring more babies receive their first vaccine doses at the six-week milestone
    • $26 million in additional funding to help GPs keep fees capped for community service card holders and those on low incomes and to prevent fee increases for under-14s.

    “Supporting GP clinics to deliver minor planned care procedures closer to patients in the community takes pressure directly off our hospitals.

    “That’s why a further $5 million to expand access to minor planned care procedures in the community will be made available to the sector once implementation details are worked through. This will reduce wait time for procedures such as minor gynaecological procedures, skin excisions, iron infusions, and oncology infusions.

    “Childhood immunisations are a key priority for this Government. We want to see 95 per cent of enrolled children fully immunised and we know GPs play a critical role in achieving that. That’s why this agreement includes performance payments for clinics that lift childhood immunisation rates by up to ten percentage points, or to 95 per cent of their enrolled population, with partial payment for partial achievement. 

    “This agreement marks a significant and positive step forward for the primary care system. It responds directly to consistent feedback from the sector over the past year about the need for a more sustainable and responsive funding model.

    “I expect this investment to deliver real results – including shorter wait times, easier access to care, and better health outcomes for patients.”

    The collection of more primary care data will further support a more effective funding approach and ensure resources are targeted at improving patient outcomes. 

    “This is part of the Government’s broader plan to rebuild and strengthen the foundations of our health system, with primary care at the centre, and to focus on performance and delivery.

    “This is the largest investment in general practice in decades – but more importantly, it’s tied to better results. Shorter wait times. Higher immunisation rates. More patients getting the care they need in the community. 

    “This is how you rebuild a health system – not with slogans, but with funding, focus, and delivery. 

    “I would like to thank the primary care sector representatives, including GenPro, GPNZ and Kāhui Tautoko who have worked with Health New Zealand in good faith on this record uplift,” Mr Brown says.

    MIL OSI New Zealand News –

    June 24, 2025
  • MIL-OSI Asia-Pac: DH to launch final phase of HPV Vaccination Catch-up Programme on June 26

    Source: Hong Kong Government special administrative region

    DH to launch final phase of HPV Vaccination Catch-up Programme on June 26???
    The Controller of the CHP, Dr Edwin Tsui said, “In Hong Kong, cervical cancer was the ninth most common cancer among women in 2022, with 522 new cases and 167 deaths. The HPV vaccine is highly effective in preventing the high-risk types of HPV that most commonly cause cervical cancer. Following the recommendations of the World Health Organization, the DH launched the first phase of Programme in December last year to provide free vaccination for female full-time students studying in Secondary Five or above (including secondary sections of special schools). As of June 8, the coverage rate for the first dose of the HPV vaccine in the first phase of the Programme has exceeded 80 per cent. The second phase has begun in mid-March this year, offering free HPV vaccination to female Hong Kong residents born between 2004 and 2008 who are currently studying at local post-secondary institutions. All post-secondary institutions have participated.”

    Under the final phase of the Programme, all female Hong Kong residents born between 2004 and 2008 who are not currently studying and have not completed their HPV vaccination only need to register with eHealth first, after which they can make an appointment through the website or telephone number of the WWS under the PHCC of the HHB for free vaccination at the WWS and its service points, or designated District Health Centre (DHC)/Express (E). Appointments can be made starting today by calling the WWS at 2855 1333 or through its website (www.wws.org.hk/vaccineIssued at HKT 17:55

    NNNN

    CategoriesMIL-OSI

    MIL OSI Asia Pacific News –

    June 24, 2025
  • MIL-OSI Europe: Answer to a written question – EMA’s role in COVID-19 vaccine approval procedures, inspections and good clinical practice checks – P-001695/2025(ASW)

    Source: European Parliament

    The highest standards in the evaluation of COVID-19 vaccines were applied by the European Medicines Agency (EMA). As for every other product it evaluates, EMA’s human medicines committee[1] (CHMP) considered the need for good clinical practice (GCP) inspections.

    Studies supporting the authorisation of a medicine must comply with GCP. Regulators can request and conduct inspections to verify compliance with the standards.

    Criteria used to select a GCP inspection is published[2]. When a GCP inspection is requested by the CHMP, EMA makes a call for available EU national GCP inspection resources.

    The Member States have the final say on whether to send inspectors for an EMA-coordinated inspection. During the COVID-19 pandemic, due to the restrictions to travel with a view to protect public health, regulators assessed the need for inspections and decided on a case-by-case basis the most appropriate and viable approach to take.

    The European Public Assessment Reports for Vaxzevria[3] and Comirnaty[4] are publicly available.

    The first cases of myocarditis that occurred in Israel in 2021 following vaccination with Comirnaty triggered a formal review by EMA[5].

    The outcome was that the risk for myocarditis and pericarditis was overall ‘very rare’ (up to one in 10 000 vaccinated people may be affected) with the highest risk in younger males[6].

    The product information of Comirnaty and Spikevax was revised adding myocarditis and pericarditis as new side effects with a warning to raise awareness.

    • [1] https://www.ema.europa.eu/en/committees/committee-medicinal-products-human-use-chmp.
    • [2] https://www.ema.europa.eu/en/documents/other/points-consider-assessors-inspectors-european-medicines-agency-inspection-coordinators-identification-triggers-selection-applications-routine-cause-inspections-their-investigation-scope-such_en.pdf.
    • [3] Vaxzevria (previously COVID-19 Vaccine AstraZeneca), INN-COVID-19-Vaccine-(ChAdOx1-S-[recombinant]) https://www.ema.europa.eu/en/documents/assessment-report/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-public-assessment-report_en.pdf.
    • [4] https://www.ema.europa.eu/en/documents/assessment-report/comirnaty-epar-public-assessment-report_en.pdf.
    • [5] https://www.ema.europa.eu/en/documents/report/report-pharmacovigilance-tasks-eu-member-states-and-european-medicines-agency-ema-2019-2022_en.pdf.
    • [6] Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 29 November — 2 December 2021 https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-29-november-2-december-2021.
    Last updated: 23 June 2025

    MIL OSI Europe News –

    June 24, 2025
  • MIL-OSI Europe: Answer to a written question – Liability exemptions in EU vaccine contracts – E-001495/2025(ASW)

    Source: European Parliament

    The (Advanced) Purchase Agreements for the supply of COVID-19 vaccines to the Member States were concluded in full transparency with the Member States. Negotiations were carried out by a Joint Negotiation Team that consisted of representatives of the Commission and of several Member States.

    This team reported regularly to a Vaccines Steering Board co-chaired by the Commission and a Participating Member State, which provided guidance throughout the process.

    The Commission has provided information to the Parliament on a continuous basis, in line with its Treaty obligations and the framework Agreement on relations between the two institutions[1].

    All mRNA vaccines that receive a marketing authorisation are based on a thorough review by the European Medicine Agency (EMA), of clinical evidence confirming a favourable benefit-risk profile.

    Adapted versions are also approved based on data showing their ability to induce an immune response that can predict clinical efficacy and safety.

    T he safety profile of all medicinal products authorised in the EU, including mRNA vaccines, is subject to continuous monitoring. There is a robust pharmacovigilance system established in the EU to detect, assess, and address potential side effects[2].

    The Commission and Member States considered early introduction of the vaccine to be in the interest of public health. Member States were therefore willing to reduce manufacturers’ risks linked to liability for adverse effects[3].

    A citizen who has suffered adverse effects from one of the COVID-19 vaccines purchased under the contracts can claim damages against the manufacturer of the vaccine[4].

    • [1] The Commission has pro-actively published redacted versions of the contracts concluded with the vaccine producers on its website.
    • [2] https://www.ema.europa.eu/en/human-regulatory-overview/pharmacovigilance-overview.
    • [3] This was intended as a risk sharing principle in the vaccine strategy.
    • [4] If the claim is successful, the Member State that administered the vaccine can, under certain conditions, be responsible for compensating the injured party and paying the vaccine manufacturer’s legal costs (indemnification).
    Last updated: 23 June 2025

    MIL OSI Europe News –

    June 24, 2025
  • MIL-OSI Europe: The challenges of vaccine production in Africa

    Source: Agenzia Fides – MIL OSI

    Thursday, 19 June 2025

    World Health Organization (WHO)

    by Cosimo GrazianiAbuja (Agenzia Fides) – In recent weeks, a Lassa fever vaccine developed by local researchers in Nigeria has shown initial signs of effectiveness in combating the disease, which recorded 747 new cases and 142 deaths in the African country in the first half of 2025. This was announced by Simeon Agwale, CEO of the Nigerian pharmaceutical company Innovative Biotech. The vaccine was developed under license from the University of Melbourne, and test doses were produced in the United States until the necessary infrastructure is established in Nigeria.For the African giant, the possibility of developing and producing this vaccine locally represents a significant achievement for the country, especially considering that the mortality rate has increased compared to 2024. This progress reflects a positive trend regarding the development of vaccines across the continent.Several African countries are striving to increase domestic vaccine production, a priority that has gained importance since the COVID-19 pandemic. In 2022, the Partnerships for African Vaccine Manufacturing (PAVM) initiative was launched, aiming to produce 60 percent of Africa’s vaccine needs by 2040 (currently just 1 percent).The challenge of vaccine manufacturing is also related to the planning and development phase.According to the Africa Centre for Disease Control and Prevention (CDC), the African Union department that deals with disease prevention and control, in 2024 there were 25 vaccine projects across the continent: 15 in early stages of development, five with production capacity but no transfer capacity, and five with both production and transfer capacity. These figures are positive and are underpinned by the fact that there are at least a dozen active pharmaceutical companies across the continent in countries such as Nigeria, Morocco, Egypt, South Africa, and Algeria. All of these aspects contribute to strengthening the vaccine ecosystem, which has already borne fruit in the past, such as the Ebola vaccine developed after the 2013 outbreak in West Africa.Three major agreements to strengthen vaccine production capacity in Africa were recently announced, one signed in December 2024 and two in February of this year. The first involved the U.S. International Development Finance Corporation, the African Development Bank, and the International Finance Corporation (IFC). It provided $45 million to VaxSen, a subsidiary of the Dakar-based Pasteur Institute in Senegal, a country also very active in vaccine research. The agreement was intended to strengthen production capacity, support the local supply chain, and create a strong vaccine distribution network, as envisioned in the African Union’s 2040 Strategy, of which PAVM is a part. In addition to its impact on healthcare, the agreement should also have an impact on the creation of skilled jobs, as the Pasteur Institute’s facilities are being expanded. The question arises whether this project will also be scaled back or even canceled following the Trump administration’s cuts in international cooperation in recent months.The first of the agreements signed in February concerns a $1.2 billion investment by Gavi-the Vaccine Alliance, a public-private partnership that supports vaccination projects worldwide, particularly for children. According to this agreement, the funds will be used to establish an RNA vaccine production platform in Africa, involving both private African companies such as the Egyptian company EVA Pharma and foreign companies such as the French company DNA Script and the Belgian companies Unizima and Quantoom Biosciences. A second agreement signed in February, however, is a purely African collaboration: Egyptian Biogeneric Pharma and South African Afrigen will expand the development of RNA vaccines to also strengthen continental expertise in manufacturing and application to combat diseases plaguing the continent.These initiatives were listed in the report published by the Coalition for Epidemic Preparedness Innovations (CEPI) in February this year. The Oslo-based foundation pointed out that among the issues that need to be resolved to develop a self-sufficient vaccine industry in Africa are problems with access to finance, production restrictions, tariffs, and customs duties and uncertain demand. The problem of the vaccine market in Africa has a major impact on the decisions of various vaccine companies around the world, also taking into account the fact that Africa’s population, especially its young population, will continue to grow strongly in the coming years. (Agenzia Fides, 19/6/2025)
    Share:

    MIL OSI Europe News –

    June 21, 2025
  • MIL-OSI Economics: Secretary-General of ASEAN meets with Secretary of the Department of Science and Technology of the Philippines

    Source: ASEAN

    Secretary-General ASEAN, Dr. Kao Kim Hourn, today met with H.E. Dr. Renato U. Solidum, Jr., Secretary of the Department of Science and Technology of the Philippines and AMMSTI Philippines, on the sidelines of the AMMSTI-21, in Jakarta, Indonesia.
     
    SG Dr. Kao commended the Philippines for its proactive and sustained leadership in advancing ASEAN’s STI agenda—including its decade-long stewardship of the ASEAN Network for Drugs, Diagnostics, Vaccines, and Traditional Medicines Innovation (ASEAN-NDI), and strategic contributions to health and disaster resilience. They also discussed preparations for the Philippines’ ASEAN Chairmanship in 2026, including Priority Economic Deliverables on artificial intelligence for health and a regional initiative on sustainable outer space. SG Dr. Kao reaffirmed ASEAN’s full support in fostering a resilient, innovative, and future-ready ASEAN.
     

    The post Secretary-General of ASEAN meets with Secretary of the Department of Science and Technology of the Philippines appeared first on ASEAN Main Portal.

    MIL OSI Economics –

    June 20, 2025
  • MIL-OSI Submissions: WHO – Global Leaders Unite to Accelerate Cervical Cancer Elimination Efforts

    Source: World Health Organization (WHO)

    New commitments at Bali Forum drive momentum to save hundreds of thousands of girls and women from cancer

    BALI, Indonesia, 19 June 2025 – Governments, donors, multilateral institutions, the private sector, and partners today announced significant policy, programmatic, and financial commitments to eliminate one of the most preventable cancers.

    At the 2nd Global Cervical Cancer Elimination Forum, hosted in Bali, Indonesia, on 17-19 June, leaders announced a wave of new investments and policy pledges to expand access to HPV vaccination, screening, and treatment – bringing the world closer to making cervical cancer the first cancer to ever be eliminated.  

    The Forum is attended by more than 300 participants, among them are high-level delegates, such as Ministers of Health from Fiji, Indonesia, Kiribati, Papua New Guinea, Rwanda, Timor-Leste, and Vanuatu, as well as Vice Ministers from Costa Rica, Paraguay, and South Africa, demonstrating strong political commitment from countries across regions.

    The Global Strategy for the elimination of cervical cancer sets clear targets for 2030: 90% of girls fully vaccinated with the HPV vaccine by age 15; 70% of women screened with a high-performance test by age 35 and again at 45; and 90% of women identified with cervical disease receiving appropriate treatment. Progress across all three pillars is essential to achieve and sustain elimination.

    “In 2018, WHO issued a global call for action to eliminate cervical cancer on the world to act, and the commitments made here in Indonesia show that call is being answered,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “But we must go further and faster. Every girl who remains unvaccinated and every woman who lacks access to screening or treatment is a reminder that equity must be at the heart of our elimination strategy. Together, we can consign cervical cancer to the history books.”

    Despite being preventable, cervical cancer still claims the life of a woman every two minutes – 94% of them in low- and middle-income countries (LMICs). Less than five per cent of women in many LMICs receive cervical cancer screening due to health system limitations, cost barriers and logistical challenges.  

    Vaccination against human papillomavirus (HPV) – the leading cause of cervical cancer – can prevent the vast majority of cases, averting 17.4 deaths for every 1000 girls vaccinated. Combined with screening and treatment—including for precancerous lesions and invasive cancer— it provides a path to elimination. However, as of 2024 only 46 per cent of low-income countries have introduced HPV vaccination nationally, compared to 98 per cent of high-income nations.

    The Bali forum builds on momentum from Cartagena, Colombia, where nearly US$ 600 million was committed last year to scale up efforts. 194 countries have adopted WHO’s global strategy to eliminate cervical cancer and 75 countries globally

    have adopted the single-dose HPV vaccine, which expands access to the vaccine to even more girls and saves costs. Vaccination coverage is also improving: in Africa, first dose coverage rose from 28% in 2022 to 40% in 2023 – making it the region with the second-highest rate globally and empowering millions of girls to protect their health and realize their potential. There is increased vaccine supply thanks to market shaping efforts by Gavi, the Vaccine Alliance and updated recommendations are helping to make cervical cancer screening and treatment more affordable.

    The Ministry of Health of the Republic of Indonesia continues to accelerate the national HPV vaccination program to reduce mortality rates from cervical cancer. Minister of Health Budi Gunadi Sadikin emphasized the urgency of this initiative, as cervical cancer remains one of the leading causes of death among women in Indonesia.

    To address this issue, the Ministry of Health is not only expanding free HPV vaccination coverage for school-age girls but also strengthening early detection programs for cervical cancer through DNA HPV test and co-testing with IVA (Visual Inspection with Acetic Acid) at health-care facilities. Additionally, the ministry is collaborating with various stakeholders, including local governments and community organizations, to enhance public education and awareness about the importance of early prevention.

    “We cannot rely solely on treatment. Prevention is far more important. Therefore, in addition to HPV vaccination, we strongly encourage regular screening so that cancer can be detected at an early stage before it progresses,” said Minister of Health Budi Gunadi Sadikin.

    Early detection significantly increases the chances of recovery and reduces treatment cost. For this reason, combining screening and vaccination is essential for effectively preventing and tackling cervical cancer.

    Alongside gains in vaccination, countries are also reporting progress in expanding access to cervical cancer screening and treatment, aligned with WHO recommendations. Innovations such as self-sampling are improving reach and feasibility, especially in low-resource settings. Many countries are scaling up national screening programmes and investing in treatment services to ensure that women who test positive receive timely and appropriate care.

    This growing global push, driven by renewed commitments from governments and partners at the Forum shows that it is possible to reverse the tide and prevent annual deaths from rising to over 410 000 by 2030, as currently estimated.

    To sustain and accelerate this momentum, donors committed to a future free from cervical cancer are strongly urged to fully fund Gavi, which aims to vaccinate an additional 120 million girls between 2026-2030, saving 1.5 million lives.

    “At its heart, this movement is about justice. It’s about ensuring that every girl and every woman, regardless of where she lives or what she earns, has access to basic, lifesaving care,” said Dr Saia Ma’u Piukala, WHO Regional Director for the Western Pacific. “As we build these services, we are not just preventing cancer, we are strengthening the bond between women and the health system. We are breaking down barriers. We are dismantling stigma. We are advancing the broader agenda for women’s health. Let us act now—so that every woman, everywhere, can live a healthy, dignified life.”

    Continued support is also essential for the coordinated efforts of governments, and global partners across the full elimination strategy to help bring us closer to a world where no girl or woman dies from a disease that there is the power to eliminate. Further, the forum calls countries to set ambitious national targets, align with global commitments, and strengthen collective action toward a cervical cancer-free world by 2030 through the Bali Declaration to Reaffirm Commitment to Cervical Cancer Elimination.

    Notes:

    Country commitments made at the forum include:

    Government of Indonesia

    Indonesia stands unwavering in its mission to eliminate cervical cancer by 2030, ensuring that every woman, regardless of socioeconomic status, can live free from its threat. With an ambitious national 90-75-90 target, Indonesia is scaling up its efforts and setting a precedent for bold, decisive action.

    Recognizing that elimination requires sustained commitment, Indonesia is mobilizing all sectors through evidence-based programming, strong local leadership, and dynamic multi-stakeholder collaboration. We are prioritizing substantial investments in the health system and fortifying the key pillars of progress—governance, financial sustainability, and social outreach—to drive real change.

    With the National Cervical Cancer Elimination Plan 2023–2030 launch, Indonesia has solidified a comprehensive partnership ecosystem spanning ministries, local governments, civil society, communities, and international development partners. Significant strides have been made across the three elimination pillars: vaccination, screening, and treatment. To accelerate our impact, Indonesia is advancing the following commitments:

    1. HPV Vaccination – Reaching Every Girl, Every Woman

    By the end of 2025, Indonesia will transition to a single-dose HPV vaccination schedule, deploying both school-based and community-based platforms to ensure 90% coverage of HPV vaccination among girls and women in all target groups by 2030.

    2. Cervical Cancer Screening – Scaling Up and Innovating

    Indonesia is dramatically expanding its screening efforts to reach 75% of women aged 30–69 by 2030, using high-performance HPV DNA testing—a globally recognized best practice. Nationwide pilots are already underway, with full-scale adoption targeted by the end of 2025.

    3. Treatment and Care – Strengthening Access and Innovation

    Indonesia is fortifying its health system by closing diagnostic and treatment services gaps. Key advancements include accelerated procurement of essential diagnostic tools and treatment equipment and expanded access to chemotherapy, immunohistochemistry testing, and cryotherapy across all regions. Additionally, we are upskilling our healthcare workforce to ensure expertise in the latest treatment techniques.

    As we move forward, Indonesia is embedding cervical cancer elimination within its broader National Cancer Control Plan 2025–2034, driving continuous monitoring, research, and evidence-based policy refinement to guarantee universal access to preventive and curative services.

    Indonesia is fully committed to accelerating progress, ensuring that every woman across the country has access to the services needed for cervical cancer prevention, early detection, and treatment. At this pivotal global forum, Indonesia with the participants of the forum urge countries to set ambitious national targets, align with global commitments, and strengthen collective action toward a cervical cancer-free world by 2030 through the adoption of Bali Declaration to Reaffirm Commitment to Cervical Cancer Elimination.

     

    Other Government commitments

    Government of Pakistan

    The Ministry of National Health Services, Regulations & Coordination reaffirms Pakistan’s unwavering commitment to cervical cancer elimination, aligning with the WHO’s 2030 targets. With over 5,000 new cases and 3,000 deaths annually, cervical cancer is a public health challenge in Pakistan. We are prioritizing a comprehensive strategy focusing on HPV vaccination for adolescent girls starting in 2025, alongside strengthening screening programs and ensuring timely treatment access.

    Our goal is to achieve a future where no woman in Pakistan loses her life to this preventable disease.

    Government of Papua New Guinea

    Papua New Guinea has committed to eliminate cervical cancer from the country. Integrated cervical cancer screening and treatment has been scaled up and the country plans to introduce HPV vaccine nationally in 2026.

    Government of Samoa

    Samoa has made major strides:

    Over 80% HPV vaccination coverage among girls aged 10–18, supported by ADB and UNICEF.
    Our first Cervical Cancer Elimination Strategy was developed in 2023 with UNFPA support.
    The National Cancer Policy and Action Plan (2024–2029) was approved by our government last December and was funded with Australian assistance.

     

    Our approach integrates screening into primary care, uses mobile outreach, and embeds community engagement through the Fa’asamoa and “Healthy Islands” principles.

    We recognise the challenges—limited resources and workforce—but we remain committed to combining prevention, screening, and partnerships to achieve our goals.

    This program is about equity, hope, and action. Every woman in Samoa deserves access to life-saving care. As a Pacific nation and proud Commonwealth member, we are determined to lead by example.

    Together, we will eliminate cervical cancer and save lives.
    Thank you for the assistance from our Development Partners and the Global Community.

    Co-host commitments

    Gates Foundation

    The Gates Foundation is committed to protecting the next generation of women from cervical cancer by increasing equitable, sustainable access to HPV vaccines in low- and middle-income countries and we are proud to support Gavi, the Vaccine Alliance, and countries in the ongoing work to accelerate the introduction and scale-up of HPV vaccines.

    We continue in our commitment that supports research on new prophylactic HPV vaccines, further studies investigating the durability of protection of single-dose vaccination, and tools to help countries better understand how vaccines might be used beyond current target populations. And we remain dedicated to our partnerships with governments, non-governmental organizations, multilateral organizations, and the private sector. Working together, we can eliminate cervical cancer.  

    Gavi, the Vaccine Alliance

    Gavi reaffirms its commitment to the Cervical Cancer Elimination Initiative by supporting lower- and middle-income countries to introduce, finance and scale up coverage of HPV vaccines to drive equitable and sustainable access.

     In partnership with countries and Alliance partners, Gavi is on track to reach its ambitious goal of protecting 86 million girls with the lifesaving HPV vaccine by the end of 2025. To date, we have supported 45 countries to introduce the HPV vaccine to their routine systems. This effort is expected to prevent more than 1.4 million future deaths from cervical cancer and represents a major step forward in advancing health equity.

    In Gavi’s next strategic period 2026–2030, Gavi aims to intensify its efforts by reaching over 120 million additional girls with the HPV vaccine- an initiative that could save 1.5 million more lives. Achieving this goal will depend on a fully funded Gavi for the next strategic period. Gavi’s investment in HPV vaccination programmes provides a strong foundation for elimination initiatives across the pillars of WHO’s Global Strategy for Cervical Cancer Elimination.

    Investing in the health of women and girls is essential to unlocking their full potential and building a healthier, more equitable future for all.

    UNICEF

    At the 2024 Forum, UNICEF announced an investment of USD 10 million towards the HPV vaccine programme (the HPV Plus initiative). Through the HPV Plus initiative and other investments and partnerships, UNICEF supported the vaccination of over 20 million girls across the 21 HPV Plus implementing countries. Importantly, UNICEF forged strong multi-sectoral engagements and partnerships, working directly with over 250,000 stakeholders in the 21 countries to ensure access for key integrated adolescent health services including nutrition, sexual and reproductive health, HIV/AIDs, menstrual hygiene management, and related services to over 490,000 girls – in addition to receiving the HPV vaccine.  

     

    In UNICEF’s next strategic plan for 2026-2029 we commit to supporting vaccination of 100 million girls with the HPV vaccine. UNICEF will continue to leverage its programmatic and multi-sectoral footprint to advance effective initiatives including integrated HPV vaccination and adolescent health services and strengthening effective delivery platforms including school-based vaccination.  We will also continue to generate and share evidence to help build stronger immunization and health programmes that advance the wellbeing of adolescent girls.

     

    UNICEF will also leverage its Maternal, Newborn, and Child Health (MNCH) program alongside its cervical cancer diagnostic toolkit to shape markets and to create linkages for the screening and treatment pillars of the cervical cancer elimination strategy. Through key programmatic touchpoints, we will raise awareness among country stakeholders and partners about effective screening and treatment options, while providing technical support where feasible.

    Unitaid

    Unitaid has been a leading investor in the secondary prevention of cervical cancer for over six years and ever since the WHO launched the call to action in 2018. This long-standing engagement reflects Unitaid’s dedication to closing the prevention gap for millions of women worldwide who are not eligible for or able to access the HPV vaccination.

    Building on this foundation, Unitaid will invest an additional US$50 million over the next two years to accelerate access to screening and pre-cancer treatment, resulting in a cumulative commitment now reaching US$130 million. This includes an immediate US$18 million investment to directly support 18 countries across Africa, Asia-Pacific, Latin America, and the Caribbean in establishing and scaling national programs. These efforts will prioritize the rapid uptake of HPV testing and pre-cancer treatment devices, decentralized screening models to reach underserved populations, and the integration of services into health systems in ways that are both sustainable and cost-effective.

    In addition to country-level support, Unitaid will strengthen regional mechanisms that benefit a broader set of countries. This includes expanding supply options to improve access to affordable commodities and fostering South-South learning structures that promote local innovation and experience sharing. Through these efforts, Unitaid aims to help countries accelerate progress toward their national cervical cancer elimination goals and contribute meaningfully to the global 90-70-90 targets.

    Civil Society Organisations

    African Cervical Health Alliance (ACHA)

    As a network of grassroots civil society organisations, activists and allies committed to advancing the health and wellbeing of African women, thus safeguarding the fabric of our communities, and nations, the African Cervical Health Alliance (ACHA) remains committed to using our knowledge of the community, our collective voices, experiences, and skills as cervical cancer survivors, caregivers and allies, in our advocacy with and for our women and girls, in the achievement of the WHO 90/70/90 targets by 2030.

    ACHA will continue scaling up the use of our evidence based, customisable IEC materials to reach at least 150,000 adolescent girls, women, parents, and community leaders across underserved communities with culturally appropriate and age-specific messages about HPV, the importance of HPV vaccination for all eligible girls, routine cervical cancer screening and access to treatment.

    We will also continue to advocate for increased HPV vaccine uptake by integrating cervical health messages into at least 100 advocacy and community engagement activities annually with key populations, including but not limited to school health programs, youth forums, and faith-based initiatives.

    We are also committed to supporting government-led efforts in our respective member countries, through technical input, stakeholder engagement, and community mobilization to adopt WHO’s recommendation for single-dose HPV vaccine schedule for our girls, and to expand access to high performance screening tests for all women, especially in rural and hard-to-reach areas.

    We stand firm in our commitment to building the advocacy capacity of grassroots champions and cancer survivors, by training at least 200 advocates by June 2026 to lead awareness campaigns, reduce stigma, and foster demand for cervical cancer prevention services.

    Our commitments remain resolute, in accelerating the elimination of cervical cancer as a public health problem across Africa, with a focus on underserved populations, and advocating for the integration of preventive services at all levels of implementation. We therefore pledge to use our unified voice, networks, and tools to catalyse political will, drive accountability, and ensure no woman or girl is left behind in the journey to a cervical cancer free Africa.

    Association for Mothers and Newborns (AMAN)

    The Association for Mothers and Newborns (AMAN) reaffirms its commitment to cervical cancer elimination, in alignment with the WHO’s 90-70-90 targets and as a national health priority of Pakistan.

    As a community-rooted professional organization, AMAN recognizes that demand generation, social mobilisation, and evidence-based advocacy are essential pillars to increase the uptake of HPV vaccination and cervical cancer screening services, particularly in underserved and marginalized communities. AMAN also provides professional training in Screening methods (Cytology, VIA), and treatment with Colposcopy, LLETZ and Surgical management.

    Through its GAVI-funded advocacy project in Sindh province (2025–26), AMAN is addressing vaccine hesitancy, countering misconceptions, and mobilizing families, community leaders, teachers, and caregivers to support HPV vaccination for adolescent girls. The initiative aims to reach over 400,000 adolescent girls, parents, and teachers via community awareness sessions, health camps, and digital outreach. It has also successfully engaged local influencers, health workers, and peer educators as advocates for cervical cancer prevention and health equity.

    AMAN pledges to collaborate with public health authorities, civil society, and global partners to amplify local voices, remove barriers, and accelerate Pakistan’s progress toward the global goal of eliminating cervical cancer as a public health problem. Together, with a multipronged approach, we can end cervical cancer.

    Cancer Awareness, Prevention and Early Detection Trust (CAPED)

    As a founding member of the Cervical Cancer Elimination Consortium – India (CCEC-I), CAPED commits to being the community engagement partner and extending outreach through its 48 partner organizations and their extended networks to support the rollout of HPV vaccination and a national cervical cancer screening program.

    By June 2026, we will coordinate efforts to:
    • Develop a national preparedness map and readiness report using real-time grassroots data, reflecting local realities on awareness, access, and health system readiness.
    • Collect and document human interest stories from communities to highlight both challenges and successes in cancer prevention efforts.
    • Create and disseminate contextually relevant communication materials that resonate with diverse audiences and address stigma, misinformation, and fear.

    These efforts will help ground national strategies in lived experiences and ensure that civil society plays a central role in advancing equitable, people-centred cervical cancer elimination in India.

    Girls and Women Health Initiative (GWHI)

    GWHI commits to double its impacts in advocacy for HPV vaccination, cervical cancer screening and treatment, along with disseminating the findings from the first ever situation analysis commissioned by the Ministry of National Health Services Regulation and Coordination, Pakistan and WHO.

    GWHI has also created the Pakistan Alliance for Cervical Cancer Elimination (PACCE), a platform to bring together all partners, governmental and non-governmental, working in Pakistan for cervical cancer elimination, to amplify efforts and impact.

    Union for International Cancer Control

    The Union for International Cancer Control is committed to working alongside its 1,150 members across 172 countries and territories to address inequities and drive global action towards the elimination of cervical cancer. With a strong reputation in global advocacy, a rich history of delivering initiatives to support national action, and flagship convening platforms that facilitate peer-to-peer exchange and foster collaboration, UICC continues to champion efforts that improve access to care, sustain progress, and lessen the impact of cervical cancer on individuals, their families and communities.

    As part of its new three-year business plan, UICC will further strengthen its engagement—including through its role in the ‘Elimination Partnership in the Indo-Pacific for Cervical Cancer’, ongoing support for cervical cancer programmes in Francophone Africa, and initiatives that amplify the voices of those with lived experience, including as part of its current three-year World Cancer Day campaign – United by Unique. A core focus of this work will be to mobilise and equip civil society to advocate for the elimination of cervical cancer—ensuring communities are heard, policies are strengthened, and accountability is upheld.

    UICC is rooted in its belief that everyone experiencing cancer should have access to quality treatment and care, and no one should die from a preventable cancer. To achieve this, UICC will leverage its established learning and knowledge-sharing opportunities, its broad multi-sectoral network, and continued advocacy to further progress and ensure that health systems are equipped to improve cancer control, and eliminate cervical cancer.

     

    Private sector

    Becton Dickinson

    Becton Dickinson HPV Access Pricing Initiative: Becton Dickinson (BD) proudly commits to a Global Access Price for our advanced HPV Screening Solution, featuring integrated Extended Genotyping and a self-collection option to expand equitable access to life-saving diagnostics globally. This all-inclusive “Price per Patient Result” will be available to governments and non-governmental organizations advancing public sector programs in 73 Low and Low-Middle Income Countries. Through multi-stakeholder collaboration, we aim to expand access, improve patient management, and help public sector programs implement high-quality, sustainable, and scalable screening programs for effective cervical cancer prevention.

    The Ministry of Health Indonesia and Becton Dickinson (BD) are partnering to expand cervical cancer screening in West Java, aiming to reach 300,000 women in three years. Building on a successful pilot in Papua, the initiative supports Indonesia’s National Action Plan, improving patient management and long-term cost-effectiveness through HPV DNA testing, self-collection, and extended genotyping.

    Roche

    Roche commits to expand affordable pricing for its cobas® HPV DNA test to 17 additional countries, bringing the total to 106 countries, with the potential to positively impact more than 600 million women worldwide. The decision reflects Roche’s unwavering dedication to continuous innovation and advancing equitable access to cervical cancer screening, a critical step in supporting countries as they work towards their elimination goals. Roche’s commitment ext

    MIL OSI – Submitted News –

    June 20, 2025
  • MIL-Evening Report: New cases of meningococcal disease have been detected. What are the symptoms? And who can get vaccinated?

    Source: The Conversation (Au and NZ) – By Archana Koirala, Paediatrician and Infectious Diseases Specialist; Clinical Researcher, University of Sydney

    Two Tasmanian women have been hospitalised with invasive meningococcal disease, bringing the number of cases nationally so far this year to 48. Health authorities are urging people to watch for symptoms and to check if they’re eligible for vaccination.

    Invasive meningococcal disease is a rare but life-threatening illness caused by the bacteria Neisseria meningitidis. Invasive means the infection spreads rapidly through the blood and into your organs.

    Early emergency medical care is important for survival and to reduce the chance of long-term complications. Even in those who survive, up to 30% suffer permanent cognitive, physical or psychological disabilities.

    Thankfully, vaccines are available to protect against it.

    How do you catch it?

    Around one in ten people carry the meningococcal bacteria in their nose or throats.

    The bacteria does not easily pass from person to person by breathing the same air or sharing drinks or food – and the bacteria do not survive well outside the human body.

    It is spread through close and prolonged contact of oral and respiratory secretions, such as saliva, from others who live in your household or through deep, intimate kissing.

    There is no way to know if you carry the bacteria, as carriers don’t have symptoms.

    Who is most at risk?

    Meningococcal disease can affect anyone.

    But infants under one, adolescents and young adults aged 15–25 years, and people without a spleen or who are immunosuppressed are at a higher risk of developing invasive disease.

    Meningococcal disease notifications by age and sex

    Babies and teens are more likely to contract the disease than other age groups.
    National Notifiable Disease Surveillance System

    Although sensitive to common antibiotics such as penicillin, the meningococcal bacteria can cause severe infection and death in a matter of hours. The difficulty in picking up meningococcal disease early is that, early on, it can mimic common viral illnesses that people would recover from without any treatment.

    Most people experience a sudden onset of fever, difficulty looking at light and/or a rash. The rash is non-blanching, meaning it doesn’t fade when you apply pressure to it. But early in the illness, it can start out as a blanching rash that fades with pressure.

    Young infants may also become irritable, have difficulty waking up, or refuse to feed.

    The bacteria usually causes a meningitis – inflammation of the lining around the brain and spinal cord – or a bloodstream infection, called septicemia or sepsis. But sometimes it can cause an infection of the bone, lungs (pneumonia) or eyes (conjunctivitis).

    Protection against different strains

    There are 13 types of meningococcal bacteria that cause invasive disease, but types A, B, C, W and Y cause the most illness.

    The rapid disease progression occurs because the bacteria has a sugar capsule which allows it to evade the immune system.

    But each of the 13 types has its own unique capsule. So immunity to one strain does not offer immunity to other strains.

    Currently, two types of vaccines are available: a vaccine that protects against meningococcal A, C, W and Y (MenACWY); and another vaccine that protects against meningococcal B.

    The vaccines are manufactured differently and therefore have different mechanisms of protection.

    The MenACWY vaccine uses parts of the sugar capsule within each of the bacteria and joins them to a protein. This is called a “conjugate vaccine” and allows for a better immune response, especially in young infants.

    The MenB vaccine does not contain the sugar capsule but includes four other proteins from the surface of the meningococcal B bacteria.

    Both vaccines are registered for all people aged six months and older, and are safe for immunocompromised people.

    The vaccines can be given from six months.
    lavizzara/Shutterstock

    MenACWY vaccine

    The MenACWY vaccine is funded under the National Immunisation Program, and given for free, to all infants aged 12 months. There is also a free catch-up program for teens in Year 10.

    The MenACWY vaccine protects against disease and also decreases the bacteria load in the throat, reducing the likelihood of transmission to others.

    MenB vaccine

    The MenB vaccine recommended for all infants aged six weeks or more. But it’s only available for free to infants in South Australia and Queensland, through state-based programs, and to Aboriginal and Torres Strait Islander infants nationally, via the National Immunisation Program.

    Parents of non-Indigenous infants in other states will pay around A$220–270 for two doses of the MenB vaccine.

    The MenB vaccine is highly protective against invasive disease for the person who receives the vaccine. But it does not eradicate the bacteria from the throat, nor does it decrease spread of the bacteria to others.

    Reducing meningococcal disease

    Other people who are at high risk of meningococcal exposure are also recommended for vaccination: people without a functional spleen, those with certain immunocompromising conditions, certain travellers and some lab workers.

    Since the rollout of the conjugate MenC vaccine in 2001 and the MenACWY in 2018, rates of invasive meningococcal disease have dropped dramatically, from 684 cases in 2002, to 136 cases in 2024. The most common strain to cause disease is now meningococcal B.

    Meningococcal notifications by jurisdiction

    Vaccination has reduced case numbers.
    National Notifiable Disease Surveillance System

    Another reason for adults to get vaccinated

    The MenB vaccine has also been shown to lower rates of another bacterial infection, gonorrhoea, by 33–47%. This is because the gonococcal bacteria is closely related and shares similar surface protein structures to meningococcal bacteria.

    In Australia, rates of gonorrhea have doubled over the past ten years , with higher rates among young Aboriginal and Torres Islander people.

    The Northern Territory began offering the vaccine to people aged 14 to 19 last year as part of a research trial.

    Further research is underway in Australia to better understand the meningococcal bacteria, its capability to evade the immune system and the cross protection against gonorrhoea.

    Archana Koirala has worked on research funded by the Australian Department of Health and Aged Care and NSW health. She is the chair of the Vaccination Special Interest Group through the Australasian Society for Infectious Diseases.

    – ref. New cases of meningococcal disease have been detected. What are the symptoms? And who can get vaccinated? – https://theconversation.com/new-cases-of-meningococcal-disease-have-been-detected-what-are-the-symptoms-and-who-can-get-vaccinated-259049

    MIL OSI Analysis – EveningReport.nz –

    June 20, 2025
  • MIL-Evening Report: New cases of meningococcal disease have been detected. What are the symptoms? And who can get vaccinated?

    Source: The Conversation (Au and NZ) – By Archana Koirala, Paediatrician and Infectious Diseases Specialist; Clinical Researcher, University of Sydney

    Two Tasmanian women have been hospitalised with invasive meningococcal disease, bringing the number of cases nationally so far this year to 48. Health authorities are urging people to watch for symptoms and to check if they’re eligible for vaccination.

    Invasive meningococcal disease is a rare but life-threatening illness caused by the bacteria Neisseria meningitidis. Invasive means the infection spreads rapidly through the blood and into your organs.

    Early emergency medical care is important for survival and to reduce the chance of long-term complications. Even in those who survive, up to 30% suffer permanent cognitive, physical or psychological disabilities.

    Thankfully, vaccines are available to protect against it.

    How do you catch it?

    Around one in ten people carry the meningococcal bacteria in their nose or throats.

    The bacteria does not easily pass from person to person by breathing the same air or sharing drinks or food – and the bacteria do not survive well outside the human body.

    It is spread through close and prolonged contact of oral and respiratory secretions, such as saliva, from others who live in your household or through deep, intimate kissing.

    There is no way to know if you carry the bacteria, as carriers don’t have symptoms.

    Who is most at risk?

    Meningococcal disease can affect anyone.

    But infants under one, adolescents and young adults aged 15–25 years, and people without a spleen or who are immunosuppressed are at a higher risk of developing invasive disease.

    Meningococcal disease notifications by age and sex

    Babies and teens are more likely to contract the disease than other age groups.
    National Notifiable Disease Surveillance System

    Although sensitive to common antibiotics such as penicillin, the meningococcal bacteria can cause severe infection and death in a matter of hours. The difficulty in picking up meningococcal disease early is that, early on, it can mimic common viral illnesses that people would recover from without any treatment.

    Most people experience a sudden onset of fever, difficulty looking at light and/or a rash. The rash is non-blanching, meaning it doesn’t fade when you apply pressure to it. But early in the illness, it can start out as a blanching rash that fades with pressure.

    Young infants may also become irritable, have difficulty waking up, or refuse to feed.

    The bacteria usually causes a meningitis – inflammation of the lining around the brain and spinal cord – or a bloodstream infection, called septicemia or sepsis. But sometimes it can cause an infection of the bone, lungs (pneumonia) or eyes (conjunctivitis).

    Protection against different strains

    There are 13 types of meningococcal bacteria that cause invasive disease, but types A, B, C, W and Y cause the most illness.

    The rapid disease progression occurs because the bacteria has a sugar capsule which allows it to evade the immune system.

    But each of the 13 types has its own unique capsule. So immunity to one strain does not offer immunity to other strains.

    Currently, two types of vaccines are available: a vaccine that protects against meningococcal A, C, W and Y (MenACWY); and another vaccine that protects against meningococcal B.

    The vaccines are manufactured differently and therefore have different mechanisms of protection.

    The MenACWY vaccine uses parts of the sugar capsule within each of the bacteria and joins them to a protein. This is called a “conjugate vaccine” and allows for a better immune response, especially in young infants.

    The MenB vaccine does not contain the sugar capsule but includes four other proteins from the surface of the meningococcal B bacteria.

    Both vaccines are registered for all people aged six months and older, and are safe for immunocompromised people.

    The vaccines can be given from six months.
    lavizzara/Shutterstock

    MenACWY vaccine

    The MenACWY vaccine is funded under the National Immunisation Program, and given for free, to all infants aged 12 months. There is also a free catch-up program for teens in Year 10.

    The MenACWY vaccine protects against disease and also decreases the bacteria load in the throat, reducing the likelihood of transmission to others.

    MenB vaccine

    The MenB vaccine recommended for all infants aged six weeks or more. But it’s only available for free to infants in South Australia and Queensland, through state-based programs, and to Aboriginal and Torres Strait Islander infants nationally, via the National Immunisation Program.

    Parents of non-Indigenous infants in other states will pay around A$220–270 for two doses of the MenB vaccine.

    The MenB vaccine is highly protective against invasive disease for the person who receives the vaccine. But it does not eradicate the bacteria from the throat, nor does it decrease spread of the bacteria to others.

    Reducing meningococcal disease

    Other people who are at high risk of meningococcal exposure are also recommended for vaccination: people without a functional spleen, those with certain immunocompromising conditions, certain travellers and some lab workers.

    Since the rollout of the conjugate MenC vaccine in 2001 and the MenACWY in 2018, rates of invasive meningococcal disease have dropped dramatically, from 684 cases in 2002, to 136 cases in 2024. The most common strain to cause disease is now meningococcal B.

    Meningococcal notifications by jurisdiction

    Vaccination has reduced case numbers.
    National Notifiable Disease Surveillance System

    Another reason for adults to get vaccinated

    The MenB vaccine has also been shown to lower rates of another bacterial infection, gonorrhoea, by 33–47%. This is because the gonococcal bacteria is closely related and shares similar surface protein structures to meningococcal bacteria.

    In Australia, rates of gonorrhea have doubled over the past ten years , with higher rates among young Aboriginal and Torres Islander people.

    The Northern Territory began offering the vaccine to people aged 14 to 19 last year as part of a research trial.

    Further research is underway in Australia to better understand the meningococcal bacteria, its capability to evade the immune system and the cross protection against gonorrhoea.

    Archana Koirala has worked on research funded by the Australian Department of Health and Aged Care and NSW health. She is the chair of the Vaccination Special Interest Group through the Australasian Society for Infectious Diseases.

    – ref. New cases of meningococcal disease have been detected. What are the symptoms? And who can get vaccinated? – https://theconversation.com/new-cases-of-meningococcal-disease-have-been-detected-what-are-the-symptoms-and-who-can-get-vaccinated-259049

    MIL OSI Analysis – EveningReport.nz –

    June 20, 2025
  • MIL-OSI Global: British holidaymaker dies from rabies: what you need to know about the disease and getting the jab if you’re going abroad this summer

    Source: The Conversation – UK – By Dan Baumgardt, Senior Lecturer, School of Physiology, Pharmacology and Neuroscience, University of Bristol

    Olexandr Panchenko/Shutterstock.com

    The recent death of a British woman from rabies after a holiday in Morocco is a sobering reminder of the risks posed by this almost universally fatal disease, once symptoms begin.

    If you’re considering travelling to a country where rabies is endemic, understanding how rabies works – and how to protect yourself – may go a long way in helping you stay safe.


    Get your news from actual experts, straight to your inbox. Sign up to our daily newsletter to receive all The Conversation UK’s latest coverage of news and research, from politics and business to the arts and sciences.


    Rabies is a zoonotic disease – meaning it is transmitted from animals to humans – and is caused by a viral infection. In 99% of cases the source of the infection is a member of the canidae family (such as dogs, foxes and wolves). Bats are another animal group strongly associated with rabies, as the virus is endemic in many bat populations.

    Even in countries that are officially rabies-free, including in their domestic animal populations – such as Australia, Sweden and New Zealand – the virus may still be found in native bat species. Other animals known to transmit rabies include raccoons, cats and skunks.

    Rabies is caused by lyssaviruses (lit. rage or fury viruses), which are found in the saliva of infected animals. Transmission to humans can occur through bites, scratches or licks to broken skin or mucous membranes, such as those in the mouth. Once inside the body, the virus spreads to eventually reach the nervous system.

    Because it causes inflammation of the brain and spinal cord, symptoms are primarily neurological, often stemming from damage to the nerve pathways responsible for sensation and muscle control.

    Patients who develop rabies symptoms often experience altered skin sensation and progressive paralysis. As the virus affects the brain, it can also cause hallucinations, and unusual or erratic behaviours. One particularly distinctive symptom – hydrophobia, a serious aversion to water – is believed to result from severe pain and difficulty associated with swallowing.

    Once rabies symptoms appear, the virus has already caused irreversible damage. At this stage, treatment is limited to supportive intensive care aimed at easing discomfort – such as providing fluids, sedation and relief from pain and seizures. Death typically results from progressive neurological deterioration, which ultimately leads to respiratory failure.

    It’s important to note that rabies symptoms can take several weeks, or even months, to appear. During this incubation period, there may be no signs that prompt people to seek medical help. However, this window is crucial as it offers the best chance to administer treatment and prevent the virus from progressing.

    Another danger lies in how the virus is transmitted. Even animals that don’t appear rabid – the classical frothing mouth and aggressive behaviour for instance – can still transmit the virus.

    Rabies can be transmitted through even superficial breaks in the skin, so minor wounds should not be dismissed or treated less seriously. It’s also important to remember that bat wounds can often be felt but not seen. This makes them easy to overlook, should there be no bleeding or clear mark on the skin.

    Don’t be tempted to pet stray animals in rabies endemic countries, not matter how cute they appear.
    cristi180884/Shutterstock.com

    The vaccine

    The good news is that there are proven and effective ways to protect yourself from rabies – either before travelling to a higher-risk area, or after possible exposure to an infected animal.

    Modern rabies vaccines are far easier to administer than older versions, which some may recall – often with discomfort. In the past, treatment involved multiple frequent injections (over 20 in all) into the abdomen using a large needle. This was the case for a friend of mine who grew up in Africa and was one day bitten by a dog just hours after it had been attacked by a hyena.

    The vaccine can now be given as an injection into a muscle, for instance in the shoulder, and a typical preventative course requires three doses. Since the protective effect can wane with time, booster shots may be needed for some individuals to maintain protection.

    Sustaining a bite from any animal should always be taken seriously. Aside from rabies, animals carry many potentially harmful bacteria in their mouths, which can cause skin and soft tissue infections – or sepsis if they spread to the bloodstream.




    Read more:
    How to treat a wound – without using superglue, grout or vodka, like some people


    First aid and wound treatment is the first port of call, and seeking urgent medical attention for any bites, scratches or licks to exposed skin or mucous membranes sustained abroad. In the UK, this also applies to any injuries sustained from bats.

    A doctor will evaluate the risk based on the wound, the animal involved, whether the patient has had previous vaccines, and in which country they were bitten, among other things. This will help to guide treatment, which might include vaccines alone or combined with an infusion of immunoglobulin infusions – special antibodies that target the virus.

    Timing is crucial. The sooner treatment is started, the better the outcome. This is why it is so important to seek medical help immediately.

    In making the decision whether you should get a vaccine before going on holiday, there are recommendations, but ultimately the choice is individual. Think about what the healthcare is like where you are going and whether you’ll be able to get treatment easily if you need it.

    Vaccines can have side-effects, though these tend to be relatively minor, and the intended benefits vastly exceed the costs. And of course avoid contact with stray animals while on holiday, despite how tempting it may be to pet them.

    Several rules of thumb can counteract the dangers of rabies: plan your holiday carefully, seek travel advice from your GP, and always treat animal bites and scrapes seriously.

    Dan Baumgardt does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

    – ref. British holidaymaker dies from rabies: what you need to know about the disease and getting the jab if you’re going abroad this summer – https://theconversation.com/british-holidaymaker-dies-from-rabies-what-you-need-to-know-about-the-disease-and-getting-the-jab-if-youre-going-abroad-this-summer-259325

    MIL OSI – Global Reports –

    June 20, 2025
  • MIL-OSI United Kingdom: Spring Booster reminder19 June 2025 ​Eligible Islanders have just under two weeks to get their COVID-19 spring booster vaccine. The vaccines are free of charge and are available at GP surgeries until Monday 30 June. Islanders need to… Read more

    Source: Channel Islands – Jersey

    19 June 2025

    Eligible Islanders have just under two weeks to get their COVID-19 spring booster vaccine. The vaccines are free of charge and are available at GP surgeries until Monday 30 June. Islanders need to contact their GP surgeries to make an appointment. 

    Islanders who are eligible for the vaccine include: 

    • those aged 75 and over 
    • those aged 6 months and over who are immunosuppressed 
    • residents in care homes for older people. 

    Residents in care homes are being vaccinated where they reside. Visit gov.je/SpringBooster for more information. 

    Primary Care Representative, Bryony Perchard, said: “It’s important that the eligible Islanders take up the offer before the end of June as they are at a higher risk of developing serious illness and being hospitalised. COVID-19 is not a seasonal illness so can affect anyone at any time. Vaccination not only reduces the chances of getting ill but also makes any infection less unpleasant.”​

    MIL OSI United Kingdom –

    June 20, 2025
  • MIL-Evening Report: Winter viruses can trigger a heart attack or stroke, our study shows. It’s another good reason to get a flu or COVID shot

    Source: The Conversation (Au and NZ) – By Tu Nguyen, PhD Candidate, Department of Paediatrics, University of Melbourne, Murdoch Children’s Research Institute

    Irina Shatilova/Shutterstock

    Winter is here, along with cold days and the inevitable seasonal surge in respiratory viruses.

    But it’s not only the sniffles we need to worry about. Heart attacks and strokes also tend to rise during the winter months.

    In new research out this week we show one reason why.

    Our study shows catching common respiratory viruses raises your short-term risk of a heart attack or stroke. In other words, common viruses, such as those that cause flu and COVID, can trigger them.

    Wait, viruses can trigger heart attacks?

    Traditional risk factors such as smoking, high cholesterol, high blood pressure, diabetes, obesity and lack of exercise are the main reasons for heart attacks and strokes.

    And rates of heart attacks and strokes can rise in winter for a number of reasons. Factors such as low temperature, less physical activity, more time spent indoors – perhaps with indoor air pollutants – can affect blood clotting and worsen the effects of traditional risk factors.

    But our new findings build on those from other researchers to show how respiratory viruses can also be a trigger.

    The theory is respiratory virus infections set off a heart attack or stroke, rather than directly cause them. If traditional risk factors are like dousing a house in petrol, the viral infection is like the matchstick that ignites the flame.

    Think of a viral infection as the matchstick that ignites the flame, leading to a heart attack or stroke.
    anokato/Shutterstock

    For healthy, young people, a newer, well-kept house is unlikely to spontaneously combust. But an older or even abandoned house with faulty electric wiring needs just a spark to lead to a blaze.

    People who are particularly vulnerable to a heart attack or stroke triggered by a respiratory virus are those with more than one of those traditional risk factors, especially older people.

    What we did and what we found

    Our team conducted a meta-analysis (a study of existing studies) to see which respiratory viruses play a role in triggering heart attacks and strokes, and the strength of the link. This meant studying more than 11,000 scientific papers, spanning 40 years of research.

    Overall, the influenza virus and SARS-CoV-2 (the virus that causes COVID) were the main triggers.

    If you catch the flu, we found the risk of a heart attack goes up almost 5.4 times and a stroke by 4.7 times compared with not being infected. The danger zone is short – within the first few days or weeks – and tapers off with time after being infected.

    Catching COVID can also trigger heart attacks and strokes, but there haven’t been enough studies to say exactly what the increased risk is.

    We also found an increased risk of heart attacks or strokes with other viruses, including respiratory syncytial virus (RSV), enterovirus and cytomegalovirus. But the links are not as strong, probably because these viruses are less commonly detected or tested for.

    What’s going on?

    Over a person’s lifetime, our bodies wear and tear and the inside wall of our blood vessels becomes rough. Fatty build-ups (plaques) stick easily to these rough areas, inevitably accumulating and causing tight spaces.

    Generally, blood can still pass through, and these build-ups don’t cause issues. Think of this as dousing the house in petrol, but it’s not yet alight.

    So how does a viral infection act like a matchstick to ignite the flame? Through a cascading process of inflammation.

    High levels of inflammation that follow a viral infection can crack open a plaque. The body activates blood clotting to fix the crack but this clot could inadvertently block a blood vessel completely, causing a heart attack or stroke.

    Some studies have found fragments of the COVID virus inside the blood clots that cause heart attacks – further evidence to back our findings.

    We don’t know whether younger, healthier people are also at increased risk of a heart attack or stroke after infection with a respiratory virus.

    That’s because people in the studies we analysed were almost always older adults with at least one of those traditional risk factors, so were already vulnerable.

    The bad news is we will all be vulnerable eventually, just by getting older.

    What can we do about it?

    The triggers we identified are mostly preventable by vaccination.

    There is good evidence from clinical trials the flu vaccine can reduce the risk of a heart attack or stroke, especially if someone already has heart problems.

    We aren’t clear exactly how this works. But the theory is that avoiding common infections, or having less severe symptoms, reduces the chances of setting off the inflammatory chain reaction.

    COVID vaccination could also indirectly protect against heart attacks and strokes. But the evidence is still emerging.

    Heart attacks and strokes are among Australia’s biggest killers. If vaccinations could help reduce even a small fraction of people having a heart attack or stroke, this could bring substantial benefit to their lives, the community, our stressed health system and the economy.

    What should I do?

    At-risk groups should get vaccinated against flu and COVID. Pregnant women, and people over 60 with medical problems, should receive RSV vaccination to reduce their risk of severe disease.

    So if you are older or have predisposing medical conditions, check Australia’s National Immunisation Program to see if you are eligible for a free vaccine.

    For younger people, a healthy lifestyle with regular exercise and balanced diet will set you up for life. Consider checking your heart age (a measure of your risk of heart disease), getting an annual flu vaccine and discuss COVID boosters with your GP.

    Tu Nguyen is supported by an Australian Government Research Training Program PhD Scholarship and a Murdoch Children’s Research Institute Top-Up Scholarship.

    Christopher Reid receives funding from National Health and Medical Research Council and the Medical Research Future Fund.

    Jim Buttery receives funding from the Medical Research Future Fund, the US Centres for Disease Control, the Coalition for Epidemic Preparedness and Innovation, Department of Foreign Affairs and Trade and the Victorian State Government.

    Diana Vlasenko and Hazel Clothier do not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and have disclosed no relevant affiliations beyond their academic appointment.

    – ref. Winter viruses can trigger a heart attack or stroke, our study shows. It’s another good reason to get a flu or COVID shot – https://theconversation.com/winter-viruses-can-trigger-a-heart-attack-or-stroke-our-study-shows-its-another-good-reason-to-get-a-flu-or-covid-shot-256090

    MIL OSI Analysis – EveningReport.nz –

    June 19, 2025
  • MIL-Evening Report: Winter viruses can trigger a heart attack or stroke, our study shows. It’s another good reason to get a flu or COVID shot

    Source: The Conversation (Au and NZ) – By Tu Nguyen, PhD Candidate, Department of Paediatrics, University of Melbourne, Murdoch Children’s Research Institute

    Irina Shatilova/Shutterstock

    Winter is here, along with cold days and the inevitable seasonal surge in respiratory viruses.

    But it’s not only the sniffles we need to worry about. Heart attacks and strokes also tend to rise during the winter months.

    In new research out this week we show one reason why.

    Our study shows catching common respiratory viruses raises your short-term risk of a heart attack or stroke. In other words, common viruses, such as those that cause flu and COVID, can trigger them.

    Wait, viruses can trigger heart attacks?

    Traditional risk factors such as smoking, high cholesterol, high blood pressure, diabetes, obesity and lack of exercise are the main reasons for heart attacks and strokes.

    And rates of heart attacks and strokes can rise in winter for a number of reasons. Factors such as low temperature, less physical activity, more time spent indoors – perhaps with indoor air pollutants – can affect blood clotting and worsen the effects of traditional risk factors.

    But our new findings build on those from other researchers to show how respiratory viruses can also be a trigger.

    The theory is respiratory virus infections set off a heart attack or stroke, rather than directly cause them. If traditional risk factors are like dousing a house in petrol, the viral infection is like the matchstick that ignites the flame.

    Think of a viral infection as the matchstick that ignites the flame, leading to a heart attack or stroke.
    anokato/Shutterstock

    For healthy, young people, a newer, well-kept house is unlikely to spontaneously combust. But an older or even abandoned house with faulty electric wiring needs just a spark to lead to a blaze.

    People who are particularly vulnerable to a heart attack or stroke triggered by a respiratory virus are those with more than one of those traditional risk factors, especially older people.

    What we did and what we found

    Our team conducted a meta-analysis (a study of existing studies) to see which respiratory viruses play a role in triggering heart attacks and strokes, and the strength of the link. This meant studying more than 11,000 scientific papers, spanning 40 years of research.

    Overall, the influenza virus and SARS-CoV-2 (the virus that causes COVID) were the main triggers.

    If you catch the flu, we found the risk of a heart attack goes up almost 5.4 times and a stroke by 4.7 times compared with not being infected. The danger zone is short – within the first few days or weeks – and tapers off with time after being infected.

    Catching COVID can also trigger heart attacks and strokes, but there haven’t been enough studies to say exactly what the increased risk is.

    We also found an increased risk of heart attacks or strokes with other viruses, including respiratory syncytial virus (RSV), enterovirus and cytomegalovirus. But the links are not as strong, probably because these viruses are less commonly detected or tested for.

    What’s going on?

    Over a person’s lifetime, our bodies wear and tear and the inside wall of our blood vessels becomes rough. Fatty build-ups (plaques) stick easily to these rough areas, inevitably accumulating and causing tight spaces.

    Generally, blood can still pass through, and these build-ups don’t cause issues. Think of this as dousing the house in petrol, but it’s not yet alight.

    So how does a viral infection act like a matchstick to ignite the flame? Through a cascading process of inflammation.

    High levels of inflammation that follow a viral infection can crack open a plaque. The body activates blood clotting to fix the crack but this clot could inadvertently block a blood vessel completely, causing a heart attack or stroke.

    Some studies have found fragments of the COVID virus inside the blood clots that cause heart attacks – further evidence to back our findings.

    We don’t know whether younger, healthier people are also at increased risk of a heart attack or stroke after infection with a respiratory virus.

    That’s because people in the studies we analysed were almost always older adults with at least one of those traditional risk factors, so were already vulnerable.

    The bad news is we will all be vulnerable eventually, just by getting older.

    What can we do about it?

    The triggers we identified are mostly preventable by vaccination.

    There is good evidence from clinical trials the flu vaccine can reduce the risk of a heart attack or stroke, especially if someone already has heart problems.

    We aren’t clear exactly how this works. But the theory is that avoiding common infections, or having less severe symptoms, reduces the chances of setting off the inflammatory chain reaction.

    COVID vaccination could also indirectly protect against heart attacks and strokes. But the evidence is still emerging.

    Heart attacks and strokes are among Australia’s biggest killers. If vaccinations could help reduce even a small fraction of people having a heart attack or stroke, this could bring substantial benefit to their lives, the community, our stressed health system and the economy.

    What should I do?

    At-risk groups should get vaccinated against flu and COVID. Pregnant women, and people over 60 with medical problems, should receive RSV vaccination to reduce their risk of severe disease.

    So if you are older or have predisposing medical conditions, check Australia’s National Immunisation Program to see if you are eligible for a free vaccine.

    For younger people, a healthy lifestyle with regular exercise and balanced diet will set you up for life. Consider checking your heart age (a measure of your risk of heart disease), getting an annual flu vaccine and discuss COVID boosters with your GP.

    Tu Nguyen is supported by an Australian Government Research Training Program PhD Scholarship and a Murdoch Children’s Research Institute Top-Up Scholarship.

    Christopher Reid receives funding from National Health and Medical Research Council and the Medical Research Future Fund.

    Jim Buttery receives funding from the Medical Research Future Fund, the US Centres for Disease Control, the Coalition for Epidemic Preparedness and Innovation, Department of Foreign Affairs and Trade and the Victorian State Government.

    Diana Vlasenko and Hazel Clothier do not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and have disclosed no relevant affiliations beyond their academic appointment.

    – ref. Winter viruses can trigger a heart attack or stroke, our study shows. It’s another good reason to get a flu or COVID shot – https://theconversation.com/winter-viruses-can-trigger-a-heart-attack-or-stroke-our-study-shows-its-another-good-reason-to-get-a-flu-or-covid-shot-256090

    MIL OSI Analysis – EveningReport.nz –

    June 19, 2025
←Previous Page
1 2 3 4 5 6 … 18
Next Page→
NewzIntel.com

NewzIntel.com

MIL Open Source Intelligence

  • Blog
  • About
  • FAQs
  • Authors
  • Events
  • Shop
  • Patterns
  • Themes

Twenty Twenty-Five

Designed with WordPress